gary%remington.%md,%phd,%frcp(c)% listofpublications%inhn.org › fileadmin › profiles ›...
TRANSCRIPT
1
Profiles November 5, 2015
Gary Remington. MD, PhD, FRCP(C)
LIST OF PUBLICATIONS
A.1. Refereed Publications
(a) MANUSCRIPTS
1. Remington G, Anisman H. Disruptive effects of epinephrine on active avoidance behavior: alteration by scopolamine and d-‐amphetamine. Pharmacol Biochem Behav, 2:424-‐430, 1974
2. Remington G, Anisman H. Genetic and ontogenetic variations in response to scopolamine and d-‐amphetamine in three strains of mice. Dev Psychobiol, 9:579-‐586, 1976
3. Anisman H, Kokkinidis L, Glazier S, Remington G. Differentiation of response biases elicited by scopolamine and d-‐amphetamine: effects on habituation. Behav Biol, 18:401-‐407, 1976
4. Remington G, Anisman H. A simple method for quantifying tremor in rodents. Pharmacol Biochem Behav, 4:721-‐723, 1977
5. Anisman H, deCantanzero D, Remington G. Escape performance following exposure to inescapable shock: deficits in motor response maintenance. J Exp Psychol, 4:197-‐218, 1978
6. Anisman H, Remington G, Sklar L. Effects of inescapable shock on subsequent escape performance: catecholaminergic and cholinergic mediation of response initiation and maintenance. Psychopharmacology, 6:107-‐124, 1979
7. Anisman H, Grimmer L, Irwin J, Remington G, Sklar LS. Escape performance after inescapable shock in selectively bred lines of mice: response maintenance and catecholaminergic activity. J Comp Physicol Psychol, 93:229-‐241, 1979
8. Remington G, Book H. DeClérambault’s syndrome, bipolar affective disorder and response to lithium. Am J Psychiatry, 141:1285-‐1287, 1984
9. Remington G, Hoffman B. Gas sniffing as a form of substance abuse. Can J Psychiatry, 29:31-‐35, 1984
10. Remington G, Jeffries JJ. Psychiatric disturbances associated with cerebral arteriovenous malformations. J Clin Psychiatry, 45:226-‐229, 1984
2
11. Jeffries JJ, Remington G, Wilkins J. The question of combined lithium/neuroleptic toxicity. Can J Psychiatry, 29:601-‐604, 1984
12. Remington G, Bezchlibnyk-‐Butler K. Ineffective sublingual lorazepam: considerations (Letter to the Editor0. J Clin Psychopharmacol, 7:365-‐367, 1987
13. Remington G. The Pisa syndrome: possible role for serotonin and noradrenaline (ltr). J Clin Psychopharmacol, 8:228-‐229, 1988
14. Remington G. Pharmacotherapy of schizophrenia. Can J Psychiatry, 34:211-‐220, 1989
15. Menuck M, Legault S, Schmidt P, Remington G. The nosologic status of the remitting atypical psychoses. Compr Psychiatry, 30:53-‐73, 1989
16. Remington G, da Costa G. Ethnocultural factors in resident supervision. Am J Psychother, 43:398-‐404, 1989
17. Remington G. Free radicals and tardive dyskinesia (ltr). Can J Psychiatry, 35:283-‐284, 1990
18. Remington G, Menuck M, Schmidt P, Legault S. The remitting atypical psychoses: clinical and nosologic considerations. Can J Psychiatry, 35:36-‐40, 1990
19. Jeffries JJ, Remington G. Drug treatment of schizophrenia. Drug Protocol, 5:25-‐30, 1990
20. Remington G, Voineskos G, Pollock B, Reed K, Coulter K. Incidence of neuroleptic-‐induced dystonia in mania versus schizophrenia. Am J Psychiatry, 147:1231-‐1233, 1990
21. Tang SW, Remington G, Persad E, Rosenblat R. Coadministration of a beta-‐adrenergic antagonist and a tricyclic antidepressant: a pilot study. Psychiatry Res, 33:101-‐106, 1990
22. Cheung SW, Tang SW, Remington GJ. Simultaneous quantitation of loxapine, amoxapine, and their 7-‐ and 8-‐hydroxy metabolites in plasma by high performance liquid chromatography. J Chromatogr, 564:213-‐221, 1991
23. Remington G, Rosenblat H. Spousal allegations of incest during transient psychotic episodes. Br J Psychiatry, 159:287-‐288, 1991
24. Fornazzari L, Remington G, Jeffries JJ. Akathisia, porphyria and low iron. Can J Psychiatry, 36:548, 1991
25. Fornazzari L, Ichise M, Remington G, Smith I. Rabbit syndrome, antidepressant use, and cerebral perfusion SPECT scan findings. J Psychiatr Neurosci, 16:227-‐229, 1991
26. Jeffries JJ, Bezchlibnyk-‐Butler, Remington G. Amenorrhea and galactorrhea associated with fluvoxamine in a loxapine-‐treated patient (ltr). J Clin Psychopharmacol, 12:296-‐297, 1992
3
27. Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan GW, Labelle A, Beauclair L, Arnott W. A Canadian multicenter placebo-‐controlled study of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol, 113:25-‐40, 1993
28. Remington G, Pollock B, Voineskos G, Reed K, Coulter K. Acutely psychotic patients receiving high-‐dose haloperidol therapy. J Clin Psychopharmacol, 13:41-‐45, 1993
29. Remington G, Prendergast P, Bezchlibnyk-‐Butler K. Dosing patterns in schizophrenia with depot, oral and combined neuroleptic therapy. Can J Psychiatry, 38:159-‐161, 1993
30. Remington G, Fornazzari L, Sethna R. Placebo response in refractory tardive akathisia. Can J Psychiatry, 38:248-‐250, 1993
31. Baskys A, Wang S, Remington G, Wojtowicz JM. Haloperidol and loxapine but not clozapine increase synaptic responses in the hippocampus. Eur J Pharmacol, 235:305-‐307, 1993
32. Remington G. Clinical use of risperidone. Can J Psychiatry, 38(suppl 3):S96-‐S100, 1993
33. Remington G, Book H. Discriminative validity of the Borderline Syndrome Index. J Pers Dis, 7:312-‐319, 1993
34. Addington DE, Jones B, Bloom D, Chouinard G, Remington G, Albright P. Reduction of hospital days in chronic schizophrenic patients treated with risperidone: a retrospective study. Curr Ther, 15:917-‐926, 1993
35. Bezchlibnyk-‐Butler K, Remington G. Use of antiparkinsonian agents in neuroleptic-‐induced extrapyramidal symptoms. Can J Psychiatry, 39:74-‐84, 1994
36. Remington G, Jeffries JJ. Erotomanic delusions and ECT: a case series. J Clin Psychiatry, 55:306-‐308, 1994
37. Schacter D, Kleinman I, Prendergast P, Remington G, Schertzer S. The effect of psychopathology on the ability of schizophrenic patients to give informed consent. J Ner Ment Dis, 182:360-‐362, 1994
38. Remington G, Adams M. Risperidone and obsessive compulsive symptoms (ltr). J Clin Psychopharmacol, 1994; 14:358-‐359
39. Remington G. Novel neuroleptics in schizophrenia: theory and clinical relevance. Can J Psychiatry, 39:S43-‐S45, 1994
40. Remington G. The long-‐term treatment of schizophrenia. Can J Psychiatry, 40 (suppl 1):S3-‐S4, 1995
41. Remington G, Adams M. Depot neuroleptic therapy: clinical considerations. Can J Psychiatry, 40(suppl 1):S5-‐S11, 1995
4
42. Kapur S., Remington GJ, Zipursky RB, Wilson AA, Houle S. The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study. Lif Sci, 57:103-‐108, 1995
43. Remington G. Understanding schizophrenia: the impact of novel antipsychotics. Can J Psychiatry, 40(suppl 2):S29-‐S32, 1995
44. Remington G. Love without romance: the complexity of erotomanic delusions (ltr). J Clin Psychiatry, 56:533-‐534, 1995
45. Remington G, Adams M. Risperidone and obsessive compulsive symptoms (Authors’ response). J Clin Psychopharmacol, 16:85-‐86, 1996
46. Jeffries JJ, Vanderhaeghe, Remington G, Al-‐Jeshi A. Clozapine-‐associated retrograde ejaculation (ltr). Can J Psychiatry, 1996; 41:62-‐63
47. Remington G, Kapur S. The relationship between serotonin and dopamine and its role in extrapyramidal symptomatology and tardive dyskinesia. J Clin Psychiatry Monogr, 14:14-‐24, 1996
48. Kapur S, Remington G. Serotonin-‐dopamine interaction and its relevance to schizophrenia. Am J Psychiatry, 153:466-‐476, 1996
49. Remington G. Topical issues on the diagnosis and drug treatment of first episode schizophrenia. J Pract Psychiatry Behav Health, 2(suppl):2S-‐9S, 1996
50. Remington G, Addington D, Collins E, Jones B, Lalonde P, MacCrimmon D, MacEwan W, Teehan M. Clozapine: current status and role in the pharmacotherapy of schizophrenia. Can J Psychiatry, 41:161-‐166, 1996
51. Remington G, Bezchlibnyk-‐Butler K. Management of neuroleptic-‐induced extrapyramidal syndromes. CNS Drugs, 5(suppl 1):21-‐35, 1996
52. Collins A, Remington G, Coulter K, Birkett K. Depression in schizophrenia: a comparison of three measures. Schizophr Res, 20:205-‐209, 1996
53. Kapur S, Remington GJ, Jones C, Wilson AA, DaSilva J, Houle S, Zipursky R. High levels of dopamine D2 receptor occupancy with low-‐dose haloperidol treatment: a PET study. Am J Psychiatry, 153:948-‐950, 1996
54. Borison RL, Daniel DG, Davidson J, DeVane L, Hansen MS, Horne R, Lieberman JA, Miller D, Remington G. Changing antipsychotic medication: guidelines on the transition to treatment with risperidone. Clin Ther, 18:592-‐607, 1996
55. Remington G. Schizophrenia: changing concepts and the development of novel antipsychotics. J Korean Soc Biol Psych, 3:22-‐29, 1996
56. Kapur S, Zipursky R, Jones C, Remington G, Wilson A, DaSilva J, Houle S. The D2 receptor occupancy of loxapine determined using PET. Neuropsychopharmacology, 15:562-‐566, 1996
5
57. Remington G, Prendergast P, Bezchlibnyk-‐Butler K. Neuroleptic dosing during the course of chronic schizophrenia: a 10-‐year follow-‐up. Can J Psychiatry, 42:53-‐57, 1997
58. Shammi CM, Remington G. Clozapine-‐induced necrotizing colitis (ltr). J Clin Psychopharmacol, 17:230-‐231, 1997
59. Tugg L, Desai D, Prendergast P, Remington G, Reed K, Zipursky R. Relationship between negative symptoms in chronic schizophrenia and neuroleptic dose, plasma levels and side effects. Schiz Res, 25:71-‐78, 1997
60. Kapur S, Zipursky R, Roy P, Jones C, Remington G, Reed K, Houle S. The relationship between D2 receptor occupancy and plasma levels on low dose oral haloperidol: a PET study. Psychopharmacology, 131:148-‐152, 1997
61. Remington G. Erotomanic delusions focused on a child (ltr). J Clin Psychiatry, 58:406, 1997
62. Collins A, Remington GJ, Coulter K, Birkett K. Insight, neurocognitive function and symptom clusters in chronic schizophrenia. Schiz Res, 27:37-‐44, 1997
63. Kapur S, Zipursky R, Remington G, Jones C, MacKay G, Houle S. PET evidence that loxapine is an equipotent blocker of 5-‐HT2 and D2 receptors: implications for the therapeutics of schizophrenia. Am J Psychiatry, 154:1525-‐1529, 1997
64. Chong S-‐A, Remington G. Ethnicity and clozapine metabolism (ltr). Br J Psychiatry, 1998; 172:97, 1998
65. Remington G, Kapur S, Zipursky R. Pharmacotherapy of first episode psychosis. Br J Psychiatry, 172(suppl 33):66-‐70, 1998
66. Remington G, Kapur S, Zipursky R. Risperidone dose, plasma levels, D2 occupancy and EPS (ltr). J Clin Psychopharmacol, 18:82-‐83, 1998
67. Remington G, Bezchlibnyk-‐Butler K. Current concepts in the pharmacotherapy of acute psychosis. CNS Drugs, 9:191-‐202, 1998
68. Nair NPV and the Risperidone Study Group. Therapeutic equivalence of risperidone given once daily and twice daily in patients with schizophrenia. J Clin Psychopharmacol, 18:103-‐110, 1998
69. Kapur S, Remington G, Zipursky RB. Does loxapine plus cyproheptadine make an atypical antipsychotic: PET analysis of its D2 and 5-‐HT2 receptor occupancy (Letter to the Editor). Arch Gen Psychiatry, 55:666-‐667, 1998
70. Kapur S, Zipursky RB, Remington G, Jones C, DaSilva J, Wilson AA, Houle S. The 5-‐HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. Am J Psychiatry, 155:921-‐928, 1998
71. Remington G, Kapur S, Zipursky R. APA guidelines for schizophrenia: risperidone equivalents (Letter to the Editor). Am J Psychiatry, 155:1301-‐1302, 1998
6
72. Iskedjian M, Hux M, Remington G. Risperidone in schizophrenia: a Canadian overview. J Psychiatr Neurosci, 23:229-‐239, 1998
73. Primeau FJ, Remington G. Evidence through clinical experience with novel antipsychotics (Editorial). Can J Psychiatry, 43(suppl 1):3S, 1998
74. Chong S-‐A, Remington G. Sertraline-‐clozapine interaction (ltr). Can J Psychiatry, 43:856-‐857, 1998
75. Kapur S, Zipursky RB, Remington G. Clinical and theoretical implications of 5-‐HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry, 156:286-‐293, 1999
76. Remington G. Old antipsychotics in today’s treatment plans. J Psychiatr Neurosci, 1999; 24:192
77. Chong S-‐A, Remington G, Tan C-‐H. Risperidone treatment of tardive dyskinesia and dystonia (ltr). J Clin Psychiatry, 1999; 60; 5:340-‐341
78. Remington G, Kapur S. D2 and 5-‐HT2 receptor effects of antipsychotics: bridging basic science and clinical findings using PET. J Clin Psychiatry, 60(suppl 10):15-‐19, 1999
79. Chong S-‐A, Remington G. Plasma olanzapine and clinical response (ltr). J Clin Psychopharmacol, 19:192-‐193, 1999
80. Remington G, Chong S-‐A, Kapur S. Distinguishing change in primary and secondary negative symptoms (ltr). Am J Psychiatry, 156:974-‐975, 1999
81. Remington G, Chong S-‐A. Conventional versus novel antipsychotics: changing concepts and clinical implications. J Psychiatr Neurosci, 24:431-‐441, 1999
82. Emsley RA and the Risperidone Working Group. Risperidone in the treatment of first-‐episode psychotic patients: a double-‐blind multicenter study. Schizophr Bull 1999; 25:721-‐729, 1999
83. Chong S-‐A, Remington GJ, Bezchlibnyk-‐Butler K. Effect of clozapine on polypharmacy. Psych Serv, 51:250-‐252, 2000
84. Fitzgerald PB, Kapur S, Caligiuri MP, Jones C, Silvestri S, Remington G, Zipursky RB. Instrumentally detected changes in motor functioning in patients with low levels of antipsychotic dopamine D2 blockade. Neuropsychopharmacology, 22:19-‐26, 2000
85. Remington G, Kapur S. Atypical antipsychotics: are some more atypical than others? Psychopharmacology, 148:3-‐15, 2000
86. Remington G. Schizophrenia: building and fixing scientific models (Editorial). Can J Psychiatry, 45:239-‐240, 2000
87. Kapur S, Wadenberg M-‐L, Remington G. Are animal models of antipsychotics appropriately dosed: Lessons from the bedside to the bench. Can J Psychiatry, 45:241-‐246, 2000
7
88. Purdon SE, Jones BDW, Stip E, Labelle A, Addington D, David SR, Brier A, Tollefson G, for the Canadian Collaborative Group for Research in Schizophrenia. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. Arch Gen Psychiatry 57:249-‐258, 2000
89. Remington G, Kapur S. Need for a new framework to understand the mechanism of all antipsychotics (Authors’ response). J Clin Psychiatry 2000; 61:387-‐388, 2000
90. Kapur S, Zipursky R, Jones C, Remington G, Houle S. Relationship between dopamine D2 occupancy, clinical response and side effects: a double blind PET study of first-‐episode schizophrenia. Am J Psychiatry, 157:514-‐520, 2000
91. Kapur S, Zipursky R, Jones C, Shammi C, Remington G, Seeman P. A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy: Arch Gen Psychiatry, 57:553-‐559, 2000
92. Chong S-‐A, Remington GJ, Lee N, Mahendran R. Contrasting clozapine prescribing patterns in the east and west? Annals of Academy Singapore, 29:75-‐78, 2000
93. Fitzgerald PB, Kapur S, Caligiuri MP, Jones C, Silvestri S, Remington G, Zipursky RB. Instrumentally detected changes in motor functioning in patients with low levels of antipsychotic dopamine D2 blockade. Neuropsychopharmacology, 22:19-‐26, 2000
94. Silvestri S, Seeman MV, Negrete JC, Houle S, Shammi CM, Remington GJ, Kapur S, Zipursky RB, Wilson A, Christensen B, Seeman P. Increased dopamine D2 receptor binding after long-‐term treatment with antipsychotics in humans: a clinical PET study. Psychopharmacology, 152: 174-‐180, 2000
95. Chong S-‐A, Remington G. Clozapine augmentation: safety and efficacy. Schizophr Bull, 26:421-‐440, 2000
96. Kapur S, Remington G. Atypical antipsychotics: patients value the lower incidence of extrapyramidal side effects (Editorial). BMJ, 321:1360-‐1361, 2000
97. Remington G, Kapur S, Zipursky RB. Antipsychotic use in first episode psychosis. Primary Psychiatry, 7:58-‐62, 2000
98. Remington G, Shammi CM, Sethna R, Sullivan R. Antipsychotic dosing patterns for schizophrenia in three treatment settings. Psych Serv, 52:96-‐98, 2001
99. Kapur S, Roy P, Daskalakis J, Remington G, Zipursky R. Increased dopamine D2 occupancy and elevated prolactin level associated with addition of haloperidol to clozapine. Am J Psychiatry, 158:311-‐314, 2001
100. Chong S-‐A, Remington G, Mahendren R, Chua H-‐C. Awareness of tardive dyskinesia in Asian patients with schizophrenia. J Clin Psychopharmacol, 21:235-‐237, 2001
8
101. Remington G, Khramov I. Health care utilization in patients with schizophrenia maintained on atypical versus conventional antipsychotics. Prog Neuro-‐Psychopharmacol & Biol Psychiat, 25:363-‐369, 2001
102. Remington G, Kapur S. SD-‐277011 Curr Opin Investig Drugs, 27:946-‐949, 2001
103. Azorin JM, Spiegel R, Remington G, Vanelle J-‐M, Pere JJ, Giguere M, Bourdeix I. A double-‐blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia. Am J Psychiatry, 158:1305-‐1313, 2001
104. Remington G, Sloman L, Konstantareas M. Clomipramine versus haloperidol in the treatment of autistic disorder: a double-‐blind crossover study. J Clin Psychopharmacol, 21:440-‐444, 2001 (response to Letter to the Editor by King et al. J Clin Psychopharmacol 22:526, 2002
105. Parker V, Remington G. ECT in treatment-‐resistant psychosis (ltr). Can J Psychiatry 46:762-‐763, 200
106. Kapur S, Remington G. Dopamine D2 blockade and ‘atypical’ antipsychotics’ mechanism of action: a necessary and sufficient explanation. Biol Psychiatry 50:873-‐883, 2001
107. Remington G. The ‘atypical’ antipsychotics: Where does ziprasidone fit? Expert Rev Neurotherapeutics 2:89-‐100, 2002
108. Koren G, Cohn T, Chitayat D, Kapur B, Remington G, Zipursky RB. The use of atypical antipsychotic medications in pregnancy and the risk for neural tube defects. Am J Psychiatry 59:136-‐137, 2002
109. Cohn T, Remington G, Kameh H. Fasting serum insulin levels in olanzapine treated patients. J Clin Psychiatry 63:75-‐76, 2002
110. Addington D, Addington J, Patten S, Remington G, Moamai J, Labelle A, Beauclair L. Double-‐blind, placebo-‐controlled comparison of the efficacy of sertraline as treatment for a major depressive episode in patients with remitted schizophrenia. J Clin Psychopharmacol 22:20-‐25, 2002
111. Tauscher J, Jones C, Remington G, Zipursky RB, Kapur S. Significant dissociation of brain and plasma kinetics with antipsychotics. Mol Psychiatry 7:317-‐321, 2002
112. Turrone P, Remington G, Kapur S, Nobrega JN. The vacuous chewing movement (VCM) model of tardive dyskinesia revisited: is there a relationship to dopamine D2 receptor occupancy? Neurosci Biobehav Rev 26:361-‐380, 2002
113. Dewa CS, Remington G, Hermann H, Fearnley J, Goering P. How much are atypical antipsychotic agents being used, and do they reach the populations who need them? A Canadian experience. Clin Ther 24:1466-‐1476, 2002
9
114. Chong SA, Mythily M, Remington G. Clinical characteristics and associated factors in antipsychotic-‐induced akathisia of Asian patients with schizophrenia. Schizophr Res 59:67-‐71, 2003
115. Turrone P, Remington G, Kapur S, Nobrega JN. The effect of dopamine D2 occupancy on vacuous chewing movements in the rat. Psychopharmacology, 165:166-‐171, 2003
116. Turrone P, Remington G, Kapur S, Nobrega J. Differential effects of within-‐day continuous versus transient D2 receptor occupancy in the development of vacuous chewing movements (VCMs) in rats. Neuropsychopharmacology, 28:1433-‐1439, 2003
117. Kiang M, Daskalakis ZJ, Christensen BK, Remington G, Kapur S. Actigraphic measurement of the effects of single-‐dose haloperidol and olanzapine on spontaneous motor activity in normal subjects. J Psychiatr Neurosci 28:293-‐299, 2003
118. Remington G. Understanding antipsychotic “atypicality”: a clinical and pharmacological moving target. J Psychiatr Neurosci 28:275-‐284, 2003
119. Stip E, Remington G, Dursun SM, Reiss JP, Rotstein E, MacEwan GW, Chokka PR, Jones B, Dickson RA and the Canadian Switch Study Group. A Canadian multi-‐centre trial assessing memory and executive functions in patients with schizophrenia spectrum disorders treated with olanzapine. J Clin Psychopharmacol 23:400-‐404, 2003
120. Fleischhacker WW, Eerdekens M, Karcher K, Remington G, Llorca P-‐M, Chrzanowski W, Martin S, Gefvert O. Treatment of schizophrenia with long-‐acting injectable risperidone: 12-‐month open-‐label trial of the first long-‐acting second-‐generation antipsychotic. J Clin Psychiatry 64:1250-‐1257, 2003
121. Jensen J, McIntosh AR, Crawley AP, Mikulis DJ, Remington G, Kapur S. Direct activation of the ventral striatum in anticipation of aversive stimuli. Neuron 40:1251-‐1257, 2003
122. Kiang M, Christensen BK, Remington G, Kapur S. Apathy in schizophrenia: clinical correlates and association with functional outcome. Schizophr Res 63;79-‐88, 2003
123. Kapur S, Sridhar N, Remington G. The newer antipsychotics: underlying mechanisms and the new clinical realities. Curr Opin Psychiatry 17:115-‐122, 2004
124. Mamo D, Remington G, Nobrega J, Hussey D, Chirakal R, Wilson AA, Baker G, Houle S, Kapur S. The effect of acute antipsychotic administration on dopamine synthesis in rodents and human subjects using 6-‐[18F]-‐L-‐m-‐tyrosine. Synapse 52:153-‐162, 2004
125. Chong S-‐A, Mythily, Remington G. Tardive dyskinesia and iron status. J Clin Psychopharmacol 24:235-‐236, 2004
10
126. Mamo D, Kapur S, Shammi CM, Papatheodorou G, Mann S, Remington G. Dopamine D2 and Serotonin 5-‐HT2 receptor occupancy at therapeutic doses of ziprasidone: a PET study. Am J Psychiatry 161:818-‐825, 2004
127. Remington G, Shammi C. The use of pharmacotherapy in the prodrome of schizophrenia. CNS Spectrums 9:579-‐586, 2004
128. Leal A, Rosillon, Mehnert A, Jarema M, Remington G. Healthcare resource utilization during 1-‐year treatment with long-‐acting, injectable risperidone. Pharmacoepidemiol Drug Safety 13:811-‐816, 2004
129. Cohn T, Prud’homme D, Streiner D, Kameh H, Remington G. Characterizing coronary heart disease risk in chronic schizophrenia: high prevalence of the metabolic syndrome. Can J Psychiatry 49:753-‐760, 2004
130. Tauscher J, Hussain T, Agid O, Verhoeff NPLG, Wilson AA, Houle S, Remington G, Zipursky R, Kapur S. Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: differentiation from other atypicals antipsychotics. Am J Psychiatry 161:1621-‐1625, 2004
131. Turrone P, Remington G, Kapur S, Nobrega JN. Continuous but not intermittent olanzapine infusion induces vacuous chewing movements in rats. Biol Psychiatry 57:406-‐411, 2005
132. Chung C, Remington G. Predictors and markers of clozapine response. Psychopharmacology 179:317-‐335, 2005
133. Remington G, Chue P, Stip E, Kopola L, Girard T, Christensen B. The crossover approach to switching antipsychotics: what is the evidence? Schizophr Res 76:267-‐272, 2005
134. Remington G. Rational pharmacotherapy of early psychosis. Br J Psychiatry 187 (suppl 38):s77-‐s84, 2005
135. Shinkai T, De Luca V, Hwang R, Matsumoto C, Hori H, Ohmori O, Remington G, Meltzer HY, Lieberman JA, Potkin SG, Nakamura J, Kennedy JL. Association study between a functional glutathione S-‐transferase (GSTP1) gene polymorphism (Ile 105Val) and tardive dyskinesia. Neurosci Lett 388:116-‐120, 2005
136. Remington G, Kapur S. Remission: what’s in a name? (ltr) Am J Psychiatry 2005; 162:2293-‐2394
137. Remington G, Saha A, Chong S-‐A, Shammi C. Pharmacological approaches to clozapine-‐resistant schizophrenia. CNS Drugs 19:843-‐872, 2005
138. Remington G, Seeman P, Shammi C, Mann S, Kapur S. ‘Extended’ antipsychotic dosing: rationale and pilot data. J Clin Psychopharmacol 6:6-‐11, 2005
139. Remington G, Shammi C. Overstating the case about recovery? (ltr) Psych Serv 56:1022, 2005
11
140. Potkin SG, Gharabawi GM, Greenspan AJ, Rupnow MF, Kosik-‐Gonzalez C, Remington G, Ruetsch C, Revicki D. Psychometric evaluation of the Readiness for Discharge Questionnaire. Schizophr Res 80:203-‐212, 2005
141. Faulkner G, Cohn T, Remington G. Validation of a physical activity assessment tool for individuals with schizophrenia. Schizophr Res 82:225-‐231, 2006
142. Remington G, Saha A, Chong S-‐A, Shammi C. Augmenting strategies in clozapine-‐resistant schizophrenia. (ltr) CNS Drugs 2006; 20:171
143. Remington G, Mamo D, Labelle A, Reiss J, Shammi C, Mannaert E, Mann S, Kapur S. A PET study evaluating dopamine D2 receptor occupancy for long-‐acting risperidone. Am J Psychiatry, 163:396-‐401, 2006
144. Saeedi H, Remington G, Christensen B. The impact of haloperidol, a dopamine D2 antagonist, on cognition and mood. Schizophr Res 85:222-‐231, 2006
145. Cohn T, Remington G, Zipursky RB, Azad A, Wolever, TMS. Insulin resistance and adiponectin levels in drug-‐free patients with schizophrenia. Can J Psychiatry 51:382-‐386, 2006
146. Remington G. Schizophrenia, antipsychotics, and schizophrenia: is there a silver lining? (Editorial) Am J Psychiatry 163:1132-‐1134, 2006
147. Zai CC, Hwang RW, De Luca V, Muller DJ, King N, Zai GC, Remington G, Meltzer HY, Lieberman JA, Potkin SG, Kennedy JL. Association study of tardive dyskinesia and twelve DRD2 polymorphisms in schizophrenia patients. Int J Neuropsychopharmacol 7:1-‐13, 2006
148. Faulkner G, Cohn T, Remington G. Validation of a physical activity assessment tool for individuals with schizophrenia. Schizophr Res 82:225-‐231, 2006
149. Faulkner G, Cohn T, Remington G, Irving H. Body mass index, waist circumference and quality of life in individuals with schizophrenia. Schizophr Res 90:174-‐178, 2007
150. Remington G, Kwon J, Collins A, Laporte D, Mann S, Christensen B. The use of electronic monitoring (MEMS®) to evaluate antipsychotic compliance in outpatients with schizophrenia. Schizophr Res 90:229-‐237, 2007
151. Faulkner G, Cohn T, Remington G. Interventions to reduce weight gain in schizophrenia. Cochrane Database Syst Rev 24(1):CD005148, 2007
152. Remington G. Tardive dyskinesia: eliminated, forgotten, or overlooked? Curr Opin Psychiatry 20:131-‐137, 2007
153. Sockalingam S, Shammi C, Remington G. Clozapine-‐induced hypersalivation: a review of treatment strategies. Can J Psychiatry 52:377-‐384, 2007
12
154. Agid O, Remington G, Kapur S, Arenovich T, Zipursky RB. Early use of clozapine for poorly responding first episode patients. J Clin Psychopharmacology 27:369-‐373, 2007
155. Renou J, De Luca V, Zai C, Bulgin N, Remington G, Meltzer HY, Lieberman JA, Le Foll B, Kennedy JL. Multiple variants of the DRD3, but not BDNF gene, influence age-‐of-‐onset of schizophrenia. Mol Psychiatry 12:1058-‐1060, 2007
156. Hazra M, Mamo DC, Remington G. Adjunctive versus monotherapeutic treatment for schizophrenia: addressing antipsychotic side effects (Letter to the Editor). Am J Psychiatry 165:396-‐397, 2008
157. Seeman MV, Clodman D, Remington G. Transient tardive dystonia: Overview and case presentation. J Clin Pract 14:251-‐257, 2008
158. Chintoh AF, Mann SW, Giacca A, Remington G. Insulin resistance following continuous, chronic olanzapine treatment: an animal model. Schizophr Res 104:23-‐30, 2008
159. Mizrahi R, Addington J, Remington G, Kapur S. Attributional style as a factor in psychosis and symptom resolution. Schizophr Res 104:220-‐227, 2008
160. Agid O, Kapur S, Remington G. Emerging drugs in schizophrenia. Exp Opin Emerging Drugs 13:479-‐495, 2008
161. Chintoh AF, Mann SW, Lam L, Lam C, Cohn TA, Fletcher PJ, Nobrega JN, Giacca A, Remington G. Insulin resistance and decreased glucose-‐stimulated insulin secretion following acute olanzapine administration. J Clin Psychopharmacol 28:494-‐499, 2008
162. Uchida H, Mamo DC, Kapur S, Labelle A, Shammi C, Mannaert EJL, Mann SW, Remington G. Monthly administration of long-‐acting risperidone and striatal dopamine D2 occupancy for the management of schizophrenia. J Clin Psychiatry 69:1281-‐1286, 2008
163. Remington G. Alterations of dopamine and serotonin transmission in schizophrenia. Prog Brain Res 172:117-‐140, 2008
164. Zai CC, Romano-‐Silva MA, Hwang R, Zai GC, Deluca V, Müller DJ, King N, Voineskos AN, Meltzer HY, Lieberman JA, Potkin SG, Remington G, Kennedy JL (2008).Genetic study of eight AKT1 gene polymorphisms and their interaction with DRD2 gene polymorphisms in tardive dyskinesia. Schizophr Res, 106:248-‐255, 2008
165. Chintoh A, Mann S, Lam L, Giacca A, Fletcher P, Nobrega J, Remington G. Insulin resistance and secretion in vivo: effects of different antipsychotics in an animal model. Schizophr Res, 108(1-‐3):127-‐133, 2009
166. Remington G. What do animal models tell us about physical and mental health (Commentary)? Mental Health and Physical Activity 2:10-‐15, 2009
167. De Luca V, Souza RP, Viggiano E, Zai CC, Shinkai T, Lieberman JA, Potkin SG, Meltzer HY, Remington G, Kennedy JL. MDR1 gene in tardive dyskinesia scale
13
scores: comparison of strategies for quantitative trait haplotype analysis. Schizophr Res 110:200-‐201, 2009
168. Ng W, Uchida H, Ismail Z, Mamo DC, Rajji TK, Remington G, Sproule B, Pollock BG, Mulsant BH, Bies RR. Clozapine exposure and the impact of smoking and gender: a population pharmacokinetic study. Ther Drug Monit 3:360-‐366, 2009
169. Zai CC, Tiwari AK, Basile V, De Luca V, Müller DJ, King N, Voineskos AN, Remington G, Meltzer HY, Lieberman JA, Potkin SG, Kennedy JL. Association study of tardive dyskinesia and five DRD4 polymorphisms in schizophrenia patients. Pharmacogenomics J 9:168-‐174, 2009
170. Sockalingam S, Shammi CM, Remington G. Treatment of clozapine-‐induced hypersalivation with ipratropium bromide: a double-‐blind, placebo-‐controlled, crossover study J Clin Psychiatry 70:1114-‐1119, 2009
171. Foussias G, Mann S, Zakzanis KK, van Reekum R, Remington G. Motivational deficits as the central link to functioning in schizophrenia: a pilot study. Schizophr Res 115:333-‐337, 2009
172. Remington G, Foussias G, Agid O. Progress in defining optimal outcome in schizophrenia, CNS Drugs 24:9-‐20, 2010
173. Novak G, Gallo A, Zai CC, Meltzer HY, Lieberman JA, Potkin SG, Voineskos AN, Remington G, Kennedy JL, Levesque D, LeFoll B. Association of the orphan nuclear receptor NR4A1 with tardive dyskinesia. Psychiatr Genet 20:39-‐43, 2010
174. Zai CC, Tiwari AK, Basile V, De Luca V, Müller DJ, Voineskos AN, Remington G, Meltzer HY, Lieberman JA, Potkin SG, Kennedy JL. Oxidative stress in tardive dyskinesia: genetic association study and meta-‐analysis of NADPH quinine oxidoreductase1 (NQO1) and superoxide dismutase 2 (SOD2, MnSOD) genes. Prog Neuropsychopharmacol Biol Psychiatry 34:50-‐56, 2010
175. Foussias G, Remington G. Antipsychotics and schizophrenia: from efficacy and effectiveness to clinical decision-‐making. Can J Psychiatry 55:117-‐125, 2010
176. Foussias G, Remington G. Negative symptoms in schizophrenia: multidimensional or Occam’s razor? Schizophr Bull, 36:359-‐369, 2010
177. Hahn MK, Cohn T, Remington G. Efficacy of metformin and topiramate in prevention and treatment of second generation antipsychotic-‐induced weight gain. (ltr) Ann Pharmacother, 44:1349-‐1350, 2010
178. Remington G. Antipsychotic dosing: still a work in progress (Editorial), Am J Psychiatry, 167:623-‐625, 2010
179. Rajji TK, Uchida H, Ismail Z, Ng W, Mamo DC, Remington G, Pollock BG, Mulsant BH. Clozapine and global cognition in schizophrenia. J Clin Psychopharmacol 30:431-‐436, 2010
14
180. Agid O, Foussias G, Remington G. Long-‐acting injectable antipsychotics in the treatment of schizophrenia: their role in relapse prevention. Exp Opin Pharmacother, 11:1-‐17, 2010
181. Remington G, Kapur S. Antipsychotic dosing: how much but also how often? Schizophr Bull, 36:900-‐903, 2010
182. Agid O, Foussias G, Remington G. Where to position clozapine: re-‐examining the evidence. Can J Psychiatry, 55:177-‐184, 2010
183. Hahn M, Remington G, Cohn T. Topiramate augmentation in clozapine-‐treated patients with schizophrenia: clinical and metabolic effects. J Clin Psychopharmacol 30:706-‐710, 2010
184. Mukundan A, Faulkner G, Cohn T, Remington G. Antipsychotic switching for patients with schizophrenia who have neuroleptic-‐induced weight or metabolic problems. Cochrane Database Syst Rev Dec 8;12:CD006629, 2010
185. Sockalingam S, Shammi C, Powell V, Barker L, Remington G. Rates of hepatitis C in clozapine-‐treated patients with schizophrenia. Schizophr Res 124:86-‐90, 2010
186. Souza RP, De Luca V, Remington G, Lieberman JA, Meltzer HY, Kennedy JL, Wong AHC. Glial cell-‐line derived neuroptrophic factor receptor alpha 2 (GFRA2) gene is associated with tardive dyskinesia. Psychopharmacology 210:347-‐354, 2010
187. Souza RP, Remington G, Chowdhury NI, Lau MK, Voineskos AN, Lieberman JA, Meltzer HY, Kennedy JL. Association study of the GSK-‐3B gene with tardive dyskinesia in European Caucasians Eur Neuropsychopharmacol 20:688-‐694, 2010
188. Souza RP, Remington G, Meltzer HY, Lieberman JA, Kennedy JL. Wong AHC. Phosphodiesterase 4B genetic variants are not associated with antipsychotic-‐induced tardive dyskineisa. Int Clin Psychopharmacol 25:264-‐269, 2010
189. Zai CC, Tiwari AK, Müller DJ, de Luca V, Shinkai T, Ni X, Sibony D, Voineskos AN, Meltzer HY, Lieberman JA, Potkin SG, Remington G, Kennedy JL. The catechol-‐O-‐methyl-‐transferase gene in tardive dyskinesia. World J Biol Psychiatry 11:803-‐812, 2010
190. Souza RP, Rosa DV, Romano-‐silva MA, Zhen M, Meltzer HY, Lieberman JA, Remington G, Kennedy JL, Wong AH. Lack of association of NALCN genetic variants with schizophrenia. Psychiatry Res, 185:450-‐452, 2010
191. Remington G, Agid O, Foussias G. Schizophrenia as a disorder of too little dopamine: implications for symptoms and treatment. Exp Rev Neurotherapeutics 11:589-‐607, 2011
192. Remington G, Seeman P, Feingold A, Mann S, Shammi C, Kapur S. ‘Extended dosing’ in the maintenance treatment of schizophrenia. J Clin Psychiatry, 72:1042-‐1048, 2011
15
193. Remington G, Mann S, McCormick P, Nobrega JN, Hahn M, Natesan S. Modeling chronic olanzapine exposure using osmotic minipumps: pharmacological limitations. Pharmacol Biochem Behav, 100:86-‐89, 2011
194. Foussias G, Mann S, Zakzanis KK, van Reekum R, Agid O, Remington G. Prediction of longitudinal functional outcomes in schizophrenia: the impact of baseline motivational deficits. Schizophr Res, 132:24-‐27, 2011
195. Chowdhury N, Remington G, Kennedy, J. Genetic mechanisms underlying clozapine-‐induced agranulocytosis. Curr Psychiatry Rep 13:156-‐165, 2011
196. Hahn M, Chintoh A, Giacca A, Xu L, Lam L, Mann S, Fletcher P, Guenette M, Cohn T, Wolever T, Arenovich T, Remington G. Atypical antipsychotics and effects of muscarinic, serotonergic, dopaminergic and histaminergic receptor binding on insulin secretion in vivo: an animal model. Schizophr Res 131:90-‐95, 2011
197. Mizrahi R, Agid O, Borlido C, Suridjan I, Rusjan P, Remington G, Wlson AA, Kapur S. Effects of antipsychotics on D3 receptors: a clinical PET study in first episode antipsychotic naive patients with schizophrenia using [11C]-‐(+)-‐PHNO. Schizophr Res 131:90-‐95, 2011
198. Souza R, Meltzer HY, Lieberman JA, Voineskos A, Remington G, Kennedy J. Prolactin as a biomarker for treatment response and tardive dyskinesia in schizophrenia subjects: old thoughts revisited through a genetic perspective. Human Psychopharmacol 26:21-‐27, 2011
199. Potkin S, Agid O, Siu C, Watsky E, Vanderburg D, Remington G. Placebo response trajectories in short-‐term and long-‐term antipsychotic trials in schizophrenia. Schizophr Res 132:108-‐113, 2011
200. Suzuki T, Remington G, Arenovich T, Uchida H, Agid O, Graff-‐Guerrero A, Mamo DC. Time course of improvement with antipsychotic medications in treatment-‐resistant schizophrenia. Br J Psychiatry 199:275-‐280, 2011
201. Suzuki T, Remington G, Mulsant B, Rajji T, Uchida H, Graff-‐Guerrero A, Mamo D. Treatment resistant schizophrenia and response to treatment: a review. Schizophr Res 133:54-‐62, 2011
202. Suzuki T, Remington G, Uchida H, Rajji TK, Graff-‐Guerrero A, Mamo DC. Management of schizophrenia in late life with antipsychotic medications: a qualitative review. Drugs Aging 28:961-‐980, 2011
203. Hazra M, Uchida H, Sproule B, Remington G, Suzuki T, Mamo DC. Impact of feedback from pharmacists in reducing antipsychotic polypharmacy in schizophrenia. Psychiatry Clin Neurosci 65:676-‐678, 2011
204. Agid O, Arenovich T, Sajeev G, Zipursky RB, Kapur S, Foussias G, Remington G. An algorithm-‐based approach to first-‐episode schizophrenia: response rates over three antipsychotic trials. J Clin Psychiatry 72:1439-‐144, 2011
205. Menon M, Schmitz TW, Anderson AK, Graff A, Korostil M, Mamo D, Gerretsen P, Addington J, Remington G, Kapur S. Exploring the neural correlates of delusions of reference. Biol Psychiatry 70:1127-‐1133, 2011
16
206. Mizrahi R, Addington J, Rusjan P, Suridjan I, Ng A, Boileau I, Pruessner JC, Remington G, Houle S, Wilson AA. Increased stress-‐induced dopamine release in psychosis. Biol Psychiatry 71:561-‐567, 2011
207. Suzuki T, Remington G, Arenovich T, Uchida H, Agod O, Graff-‐Guerrero A, Mamo DC. Time course of improvement with antipsychotic medication in treatment-‐resistant schizophrenia. Br J Psychiatry 199:275-‐280, 2011
208. Taylor VH, McIntyre RS, Remington G, Levitan R, Stonehocker B, Sharma AM. Beyond pharmacotherapy: understanding the links between obesity and the chronically mentally ill. Can J Psychiatry 57:5-‐12, 2012
209. Tiwari AK, Zai CC, Likhodi O, Voineskos AN, Meltzer HY, Lieberman JA, Potkin SG, Remington G, Müller DJ, Kennedy JL. Association study of cannibinoid receptor 1 (CNR1) gene in tardive dyskinesia. Pharmacogenomics J 12:260-‐266, 2012
210. Callaghan RC, Cunningham JK, Allebeck P, Arenovich T, Sajeev G, Remington G, Boileau I, Kish SJ. Methamphetamine use and schizophrenia: a California cohort study. Am J Psychiatry 169:389-‐396, 2012
211. Remington G, Kapur S, Foussias G, Agid O, Mann S, Borlido C, Richards S, Javaid D. Tetrabenazine augmentation in treatment-‐resistant schizophrenia: a 12-‐week, double-‐blind, placebo-‐controlled trial. J Clin Psychopharmacol 32:95-‐99, 2012
212. Mizuno Y, Bies RR, Remington G, Mamo DC, Suzuki T, Pollock BG, Tsuboi T, Watanabe K, Mimura M, Uchida H. Dopamine D2 receptor occupancy with risperidone or olanzapine during maintenance treatment of schizophrenia. Prog in Neuropsychopharmacol Biol Psychiatry 37:182-‐187, 2012
213. Suzuki T, Remington G, Mulsant B, Uchida H, Rajji T, Graff-‐Guerrero A, Mimura M, Mamo D. Defining treatment-‐resistant schizophrenia and response to antipsychotics: a review and recommendations. Psychiatry Res 197:1-‐6, 2012
214. Sinyor M, Remington G. Is psychiatry ignoring suicide? The case for clozapine. J Clin Psychopharmacol 32:307-‐308, 2012
215. Fervaha G, Remington G. Interpreting a multivariate analysis of functional neuroimaging data. Front Psychiatry, 2012; 3:52. doi: 10.3389/fpsyt.2012.00052.
216. Gohlke JM, Dhurandhar EJ, Correll CU, Morrato EH, Newcomer JW, Remington G, Nasrallah HA, Crystal S, Nicol G, Adipogenic and Metabolic Effects of Antipsychotic Drugs Speakers, Allison D. Recent advances in understanding and mitigating adipogenic and metabolic effects of antipsychotic drugs. Front Neuropharmacol 2012;3:52. doi: 10.3389/fpsyt.2012.00062. Epub 2012 Jun 28
217. Seeman P, Remington G. Antipsychotic dosing: extended, and transient. Clin Schizophr Relat Psychoses 6:86-‐87, 2012
218. Agid O, McDonald K, Siu C, Tsoutsoulas C, Wass C, Zipursky RB, Foussias G, Remington G. Happiness in first-‐episode schizophrenia. Schizophr Res 141:98-‐103, 2012
17
219. Yilmaz Y, Zai CC, Hwang R, Mann S, Arenovich T, Remington G, Daskalakis ZJ. Antipsychotics, dopamine D2 receptor occupancy and clinical improvement in schizophrenia: a meta-‐analysis. Schizophr Res, 140:214-‐220, 2012
220. Ikai S, Remington G, Suzuki T, Takeuchi H, Tsuboi T, Den R, Hirano J, Tsunoda K, Nishimoto M, Watanabe K, Mimura M, Mamo DC, Uchida H. A cross-‐sectional study of plasma risperidone levels with risperidone long-‐acting injectable: implications for dopamine D2 receptor occupancy during maintenance treatment in schizophrenia. J Clin Psychiatry 73:1147-‐1152, 2012
221. Remington G, Foussias G, Agid O, Hahn M, Takeuchi H, Rao N. Anti-‐schizophrenia drugs: the next generation. JPPS 9:49-‐51, 2012
222. Remington G, Agid O, Foussias G, Hahn M, Rao N, Sinyor M. Clozapine’s role in the treatment of first-‐episode schizophrenia. Am J Psychiatry 170:164-‐151, 2013
223. Menon M, Addington J, Remington G. Examining cognitive biases in patients with delusions of reference. Eur Psychiatry 28:71-‐73, 2013
224. Hahn M, Cohn T, Remington G. Topiramate in schizophrenia: a review of effects on psychopathology and metabolic parameters. Schizophrenia & Related Psychoses 186-‐196, 2013
225. Remington G, Agid O, Foussias G, Fergusson L, McDonald K, Powell V. Clozapine and therapeutic drug monitoring: is there sufficient evidence for an upper threshold? Psychopharmacology 225:505-‐518, 2013
226. Guenette MD, Hahn M, Cohn TA, Remington GJ. Atyipical antipsychotics and diabetic ketoacidosis: a review. Psychopharmacology 226:1-‐12, 2013
227. Fervaha G, Remington G. Neuroimaging findings in schizotypal personality: a systematic review. Prog Neuropsychopharmacol Biol Psychiatry 43:96-‐107, 2013
228. Suzuki T, Graff-‐Guerrero A, Uchida H, Remington G, Caravaggio F, Borlido C, Pollock B, Mulsant B, De Luca V, Ismail Z, Mamo D. Dopamine D2/D3 occupancy of ziprasidone across a day: a within-‐subject PET study. Psychopharmacology 228:43-‐51, 2013
229. Mann S, Chintoh A, Giacca A, Fletcher P, Nobrega J, Hahn M, Remington G. Chronic olanzapine administration in rats: effects of route of administration on weight, food intake and body composition Pharmacol Biochem Behav 103:717-‐722, 2013
230. McCormick PN, Wilson VS, Wilson AA, Remington G. Acutely administered antipsychotic drugs are highly selective for dopamine D2 over D3 receptors. Pharmacol Res 70;66-‐71, 2013
231. Remington G, Teo C, Mann S, Hahn M, Foussias G, Agid O. Examining levels of antipsychotic adherence to better understand nonadherence. J Clin Psychopharmacol 33:261-‐261, 2013
18
232. Gorczynski P, Faulkner G, Cohn T, Remington GJ. Examining the efficacy of point-‐of-‐choice prompts on stair usage in a psychiatric setting. Psych Serv 64:498, 2013
233. Guenette MD, Giacca A, Hahn M, Teo C, Lam L, Chintoh A, Arenovich T, Remington G. Atypical antipsychotics and effects of adrenergic and serotonergic receptor binding on insulin secretion in-‐vivo: an animal model. Schizophr Res 146:162-‐169, 2013
234. Voineskos AN, Foussias G, Lerch JP, Felsky D, Remington G, Rajji TK, Lobaugh NJ, Pollock BG, Mulsant BH. Neuroimaging evidence for the schizophrenia deficit subtype JAMA Psychiatry 70:472-‐480, 2013
235. Rao N, Remington G. Investigational drugs for schizophrenia targeting the dopamine receptor: Phase II trials. Exp Opin Invest Drugs 22:881-‐894, 2013
236. Takeuchi H, Remington G. A systematic review of reported cases involving psychotic symptoms worsened by aripiprazole in schizophrenia or schizoaffective disorder. Psychopharmacology 228:175-‐185, 2013
237. Guenette MD, Powell V, Johnston K, Foussias G, Agid O, Hahn M, Takeuchi H, Remington G. Risk of neutropenia in a clozapine-‐treated geriatric population. Schizophr Res 148:3-‐5, 2013
238. Chan LF, Zai C, Monda M, Potkin S, Kennedy JL, Remington G, Lieberman J, Meltzer HY, De Luca V. Role of ethnicity in antipsychotic-‐induced weight gain and tardive dyskinesia: genes or environment? Pharmacogenomics 14:1273-‐1281, 2013
239. Fervaha G, Agid O, Takeuchi H, Foussias G, Remington G. Life satisfaction with schizophrenia in the Clinical Antipsychotic Trial of Intervention Effectiveness (CATIE) study. Am J Psychiatry 170:1061-‐1062, 2013
240. Fervaha G, Agid O, Takeuchi H, Foussias G, Remington G. Clinical determinants of life satisfaction in chronic schizophrenia: data from the CATIE study. Schizophr Res 170:1061-‐1063, 2013
241. Fervaha G, Graff-‐Guerrero A, Zakzanis KK, Foussias G, Agid O, Remington G. Incentive motivation deficits in schizophrenia reflect effort computation impairments during cost-‐benefit decision making. J Psychiatr Res 47:1590-‐1596, 2013
242. Zai CC, Tiwari AK, Mazzoco M, de Luca V, Mueller DJ, Shaikh SA, Lohoff FW, Freeman N, Voineskos AN, Potkin SG, Lieberman JA, Meltzer HY, Remington G, Kennedy JL. Association study of the vesicular monoamine transporter gene SLC18A2 with tardive dyskinesia. J Psychiatr Res 47:1760-‐1765, 2013
243. Takeuchi H, Suzuki T, Bies RR, Remington G, Mamo DC, Pollock BG, Mimura M, Uchida H. Estimated D2 receptor occupancy from plasma concentrations of atypical antipsychotics and subjective experience/drug attitude in schizophrenia: an analysis of the CATIE data. Schizophr Res 150:373-‐379, 2013
19
244. Fervaha G, Agid O, Foussias G, Remington G. Impairments in both reward and punishment guided reinforcement learning in schizophrenia. Schizophr Res 150:592-‐593, 2013
245. Fervaha G, Foussias G, Agid O, Remington G. Amotivation and functional outcomes in schizophrenia. Psychiatry Res 210:665-‐668, 2013
246. Farooq S, Agid O, Foussias G, Remington G. Using treatment response to subtype schizophrenia: proposal for a new paradigm in classification. Schizophr Bull 39:1169-‐1172, 2013
247. Hahn M, Wolever T, Arenovich T, Teo C, Giacca A, Powell V, Clarke L, Fletcher P, Cohn T, McIntyre RS, Gomes S, Chintoh A, Remington G. Acute effects of single-‐dose olanzapine on metabolic, endocrine, and inflammatory markers in healthy controls. J Clin Psychopharmacol 33:740-‐746, 2013
248. Callaghan RC, Veldhuizen S, Jeysingh T, Orlan C, Graham C, Kakouris G, Remington G, Gatley J. Patterns of tobacco-‐related mortality among individuals with schizophrenia, bipolar disorder, or depression. J Psychiatr Res 48:102-‐110, 2013
249. Agid O, Siu C, Pappadopulos E, Vanderburg D, Remington G. Early prediction of clinical and functional outcome in schizophrenia. Eur Neuropsychopharmacol 23:842-‐851, 2013
250. Agid O, Schulze L, Arenovich T, Sajeev G, McDonald K, Foussias G, Fervaha G, Remington G. Antipsychotic response in first-‐episode schizophrenia: efficacy of high doses and switching. Eur Neuropsychopharmacol 23:1017-‐1022, 2013
251. Moriguchi S, Bies RR, Remington G, Suzuki T, Mamo DC, Watanabe K, Mimura M, Pollock BG, Uchida H. Estimated dopamine D2 occupancy and remission in schizophrenia: analysis of the CATIE data. J Clin Psychopharmacol 33:682-‐685, 2013
252. Agid O, Siu C, Potkin SG, Kapur S, Watsky E, Vanderburg D, Zipursky RB, Remington G. Meta-‐regression analysis of placebo response in antipsychotic trials 1970-‐2010. Am J Psychiatry 170:1335-‐1344, 2013
253. Fervaha G, Agid O, Takeuchi H, Foussias G, Remington G. Clinical determinants of life satisfaction in chronic schizophrenia. Data from the CATIE study. Schizophr Res 151:203-‐208, 2013
254. Takeuchi H, Suzuki T, Remington G, Bies RR, Abe T, Graff-‐Guerrero A, Watanabe K, Mimura M, Uchida H. Effects of risperidone and olanzapine dose reduction on cognitive function in stable patients with schizophrenia: an open-‐label, randomized, controlled, pilot study. Schizophr Bull 39:993-‐998, 2013
255. Fervaha G, Foussias G, Agid O, Remington G. Neural substrates underlying the computation effort in schizophrenia. Neurosci Biobehav Rev 37:2469-‐2475, 2013
256. Siu CO, Agid O, Remington G. Bias in efficacy ranking using indirect comparisons: network structure and placebo. Lancet 382 (9905):1874, 2013
20
257. Zawadski JA, Girard TA, Foussias G, Rodrigues A, Siddiqui I, Lerch JP, Grady C, Remington G, Wong A. Simulating real world functioning in schizophrenia using a naturalistic city environment and single-‐trial, goal-‐directed navigation. Fr Behav Neurosci Nov 26;7:180, 2013
258. Remington G, Hahn M. Off-‐label antipsychotic use and tardive dyskinesia in at-‐risk populations: new drugs with old side effects. J Psychiatry Neurosci 39:E1-‐2, 2013
259. Fervaha G, Remingon G. Invalid responding in questionnaire-‐based research: implications for the study of schizotypy. Psychol Assess 25:1355-‐1360, 2013
260. Lee J, Remington G. Adequate dosing for second-‐generation antipsychotics in establishing treatment resistance in schizophrenia. Am J Psychiatry (ltr) 171:118-‐119, 2014
261. Rao N, Remington G. Targeting the dopamine receptor in schizophrenia: investigational drugs in Phase III trials. Exp Opin Pharmacother 15(3):373-‐383, 2014
262. Remington G, Foussias G, Fervaha G, Agid O. Schizophrenia, cognition, and psychosis. JAMA Psychiatry (ltr) 71:336-‐337, 2014
263. Hahn MK, Chintoh A, Remington G, Teo C, Mann S, Aenovich T, Fletcher P, Lam L, Nobrega J, Guenette M, Cohn T, Giacca A. Effects of intracerebroventricular (ICV) olanzapine on insulin sensitivity and secretion in vivo: an animal model. Eur Neuropsychopharmacol 24(3):448-‐458, 2014
264. Guenette MD, Chintoh A, Remington G, Hahn M. Atypical antipsychotic-‐induced metabolic disturbances in the elderly. Drugs Aging 31(3):159-‐184, 2014
265. Yoshida K, Bies RR, Suzuki T, Remington G, Pollock BG, Mizuno Y, Miniura M, Uchida H. Tardive dyskinesia in relation to estimated dopamine D2 receptor occupancy in patients with schizophrenia: analysis of the CATIE data. Schizophr Res 153(1-‐3):184-‐188, 2014
266. Remington G, Foussias G, Agid O, Fervaha G, Takeuchi H, Hahn M. The neurobiology of relapse in schizophrenia. Schizophr Res 152:381-‐390, 2014
267. Lee J, Nurjono M, Tay YH, Lee TS, Remington G. A comparison of cardio-‐metabolic risk between the deficit and non-‐deficit subtypes of schizophrenia. Schizophr Res (ltr) 153:246-‐247, 2014
268. Takeuchi H, Suzuki T, Remington G, Watanabe K, Mimura M, Uchida H. Lack of effect of risperidone or olanzapine dose reduction on subjective experiences in stable patients with schizophrenia. Psychiatr Res 218(1-‐2):244-‐246, 2014
269. Fervaha G, Agid O, Foussias G, Remington G. Toward a more parsimonious assessment of neurocogntion in schizophrenia: a 10-‐minute assessment tool. J Psych Res 52:50-‐56, 2014
21
270. Remington G, Fervaha G, Foussias G, Agid O, Turrone P. Antipsychotic dosing: found in translation J Psychiatry Neurosci 39:223-‐231, 2014
271. Lister J, 231. Oxidative stress and the antipsychotic-‐induced vacuous chewing movement model of tardive dyskinesia: evidence for antioxidant-‐based prevention strategies. Psychopharmacology 231(11):2237-‐2249, 2014
272. Fervaha G, Remington G. Validation of an abbreviated quality of life scale for schizophrenia. Eur Neuropsychopharmacol 52:50-‐56, 2014
273. Fervaha G, Foussias G, Siddiqui I, Agid O, Remington G. Abbreviated quality of life scales for schizophrenia: comparison and utility of two brief community functioning measures. Schizophr Res 154:89-‐92, 2014
274. Arbour-‐Nicitopoulos KP, Duncan M, Remington J, Cairney J, Faulkner GE. Development and reliability testing of a health action process approach inventory for physical activity participation among individuals with schizophrenia. Front Psychiatry 5:1-‐9 (Article 68), 2014
275. Lee J, Lee T, Remington G. Schizophrenia: no health without physical health. Ann Acad Med Singapore (Editorial) 43:248-‐249, 2014
276. Fervaha G, Agid O, McDonald K, Foussias G, Remington G. Daily activity patterns in remitted first-‐episode schizophrenia. Compr Psychiatry 55:1182-‐1187, 2014
277. Lee J, Takeuchi H, Remington G. Comparing dopamine D2 receptor occupancies for use in clinical practice: attractive proposition but fraught with pitfalls. J Clin Psychopharmacol (ltr) 34(4):530-‐532, 2014
278. Foussias G, Agid O, Fervaha G, Remington G. Negative symptoms of schizophrenia: clinical features, relevance to real world functioning and specificity versus other CNS disorders. Eur Neuropsychopharmacol 24:693-‐709, 2014
279. Takeuchi H, Suzuki T, Remington G, Watanabe K, Mimura M, Uchida H. Lack of effect of risperidone or olanzapine dose reduction on metabolic parameters, prolactin, and corrected QT interval in stable patients with schizophrenia. J Clin Psychopharmacol (ltr) 34(4):517-‐520, 2014
280. Lee J, Powell V, Remington G. Mean platelet volume in schizophrenia after 1 year of clozapine exposure. Schizophr Res 157:134-‐136, 2014
281. Kalahani-‐Bargis K, Foussias G, Remington G, Zakzanis K, Jeffay E. C-‐23 longitudinal analysis of verbal fluency in chronic schizophrenia. Arch Clin Neuropsychol 29(6):580-‐581, 2014
282. Fervaha G, Zakzanis KK, Foussias G, Graff-‐Guerrero A, Agid O, Remington G. Motivational deficits and cognitive test performance in schizophrenia. JAMA Psychiatry 71(9):1058-‐1065, 2014
283. Fervaha G, Foussias G, Agid O, Remington. Impact of primary negative symptoms on functional outcomes in schizophrenia. Eur Psychiatry 130:1290-‐1299, 2014
22
284. Fervaha G, Foussias G, Agid O, Remington G. Motivational and neurocognitive deficits are central to the prediction of longitudinal functional outcome in schizophrenia. Acta Psychiatrica Scandinavica 130:290-‐299, 2014
285. Plitman E, Nakajima S, de la Fuente-‐Sandoval C, Gerretsen P, Chakravarty MM, Kobylianskii J, Chung JK, Caravaggio F, Iwata Y, Remington G, Graff-‐Guerrero A. Glutamate-‐mediated excitotoxicity in schizophrenia: a review. Eur Neuropsychopharmacol 24:1591-‐1605, 2014
286. Lee J, Takeuchi H, Fervaha G, Bhaloo A, Powell V, Remington G. Relationship between clinical improvement and functional gains with clozapine in schizophrenia. Eur Neuropsychopharmacol 24:1622-‐1629, 2014
287. Lee J, Powell V, Remington G. Therapeutic drug monitoring of clozapine: sampling error as a source of variance. Ther Drug Monit 36:829-‐831, 2014
288. Caravaggio F, Shinichiro N, Borlido C, Remington G, Gerretsen P, Wilson A, Houle S, Menon M, Mamo D, Graff-‐Guerrero A. Estimating endogenous dopamine levels at D2 and D3 receptors in humans using the agonist radiotracer [11C]-‐(+)-‐PHNO. Neuropsychopharmacology 39:2769-‐2776, 2014
289. Takeuchi H, Suzuki T, Bies RB, Remington G, Watanabe K, Mimura M, Uchida H. Dose reduction of risperidone or olanzapine and estimated dopamine D2 receptor occupancy in stable patients with schizophrenia: findings from an open-‐label, randomized controlled study. J Clin Psychiatry 75:1209-‐1214, 2014
290. Gerretsen P, Remington G, Borlido C, Quilty L, Hassan S, Polsinelli G, Teo C, Mar W, Simon R, Menon M, Pothier DD, Nakajima S, Caravaggio F, Mamo DC, Rajji TK, Mulsant BH, Deluca V, Ganguli R, Pollock BG, Graff-‐Guerrero A. The VAGUS insight into psychosis scale – self-‐report and clinician-‐related versions. Psychiatry Res 220:1084-‐1089, 2014
291. Li CH, Stratford RE Jr, Velez de Mendizabal N, Cremers TI, Pollock B, Mulsant B, Remington G, Bies RR. Prediction of brain clozapine and norclozapine concentrations in humans from a scaled pharmacokinetic model for rat brain and plasma pharmacokinetics. J Transl Med 12:1-‐11, 2014
292. Gorczynski P, Faulkner G, Cohn T, Remington G. Examining strategies to improve accelerometer compliance for individuals living with schizophrenia. Psychiatr Rehabil J 37:333-‐335, 2014
293. Gerretsen P. Menon M, Mamo DC, Fervaha G, Remington G, Pollock BG, Graff-‐Guerrero A. Impaired insight into illness and cognitive insight in schizophrenia spectrum disorders: resting state functional connectivity. Schizophr Res 160:42-‐50, 2014
294. Rao NP, Remington G. Targeting the dopamine receptor in schizophrenia: investigational drugs in Phase III trials. Expert Opin Pharmacother 15:373-‐383, 2014
295. Kenk M, Selvanathan T, Rao N, Suridjan I, Rusjan P, Remington G, Meyer JH, Wilson AA, Houle S, Mizrahi R. Imaging neuroinflammation in gray and white
23
matter in schizophrenia: an in-‐vivo PET study with [18F]-‐FEPPA. Schizophr Bull 41:85-‐93, 2015
296. McCormick PN, Fletcher PJ, Wilson VS, Browne JDC, Nobrega JN, Remington GJ. Low dose pramipexole causes D3 receptor-‐independent reduction of locomotion and responding responding for a conditioned reinforcer. Neuropharmacology 89:225-‐231, 2015
297. Fervaha G, Agid O, Takeuchi H, Lee J, Foussias G, Zakzanis KK, Graff-‐Guerrero A, Remington G. Extrapyramidal symptoms and cognitive test performance in patients with schizophrenia. Schizophr Res 161:351-‐356, 2015
298. Foussias G, Siddiqui I, Fervaha G, Agid O, Remington G. Dissectinng negative symptoms in schizophrenia:opportunities for translation into new treatments. J Psychopharmacol 29:116-‐126, 2015
299. Nakajima S, Takeuchi H, Fervaha G, Plitman E, Chung J, Caravaggio F, Iwata I, Mihashi Y, Gerretsen P, Remington G, Graff-‐Guerrero A. Comparative efficacy between clozapine and other antipsychotics on depressive symptoms in patients with schizophrenia: analysis of the CATIE Phase 2E data. Schizophr Res 161:429-‐433, 2015
300. Sinyor M, Schaffer A, RemingtonG. Suicide in schizophrenia: an observational study of coroner records in Toronto. J Clin Psychiatry 76:e98-‐e103, 2015
301. Hahn MK, Gomes S, Remington GJ. Low-‐dose, off-‐label quetiapine use, metabolic syndrome and fasting glucose in an eldery man: a case report. Brain Disord Ther 4(1): 1000149, 2015
302. Lee J, Remington G. Schizophrenia as a lifelong illness: implications for care. Ann Acad Med Sing 44:26-‐28, 2015
303. Fervaha G, Agid O, Takeuchi H, Foussias G, Lee J, Remington G. Clinical and functional outcomes in people with schizophrenia with a high sense of well-‐being. J Nerv Ment Dis 203:187-‐193, 2015
304. Takeuchi H, Fervaha G, Lee J, Agid O, Remington G. Effectiveness of different dosing regimens of risperidone and olanzapine in schizophrenia. Eur Neuropsychopharmacol 25:295-‐302, 2015
305. Fervaha G, Agid O, Takeuchi H, Lee J, Foussias G, Remington G. Relationship between symptomatic improvement and overall illness severity in patients with schizophrenia. J Clin Psychopharmacol 35:128-‐133, 2015
306. Remington G, Agid O, Foussias G, Fervaha G, Takeuchi H, Lee J, Hahn M. What does schizophrenia teach us about antipsychotics? Can J Psychiatry 60 (3, Suppl 2):S14-‐S18, 2015
307. Siu C, Agid O, Remington G. Meta-‐analysis of treatment response in antipsychotic clinical trials (ltr) JAMA Psychiatry 72(5):514-‐515, 2015
24
308. Lister J, Fletcher PJ, Nobrega JN, Remington G. Behavioural effects of food-‐derived opioid-‐like peptides in rodents: implications for schizophrenia? Pharmacol Biochem Behav 134:70-‐78, 2015
309. Fervaha G, Takeuchi H, Lee J, Foussias G, Fletcher P, Agid O, Remington G. Antipsychotics and amotivation. Neuropsychopharmacology 40:1539-‐1548, 2015
310. Nakajima S, Takeuchi H, Plitman E, Fervaha G, Gerretsen P, Caravaggio F, Chung JK, Iwata Y, Remington G, Graff-‐Guerrero A. Neuroimaging findings in treatment-‐resistant schizophrenia: a systematic review. Lack of neuroimaging correlates of treatment-‐resistant schizophrenia. Schizophr Res 164(1-‐3):164-‐175, 2015
311. Carvaggio F, Borlido C, Hahn M, Feng Z, Fervaha G, Gerretsen P, Nakajima S, Plitman E, Chung JK, Iwata Y, Wilson A, Remington G, Graff-‐Guerrero A. Reduced insulin sensitivity is related to less endogenous dopamine at D2/D3 receptors in the ventral striatum of healthy non-‐obese humans. Int J Neuropsychopharmacol 18(7):1-‐10, 2015
312. Wheeler AL, Wessa M, Szeszko PR, Foussias G, Chakravarty MM, Lerch JP, DeRosse P, Remington G, Mulsant BH, Linke J, Malhotra AK, Voineskos AN. Further neuroimaging evidence for deficit subtype of schizophrenia: a cortical connectomics analysis. JAMA Psychiatry 72(5):446-‐455, 2015
313. Tsuboi T, Suzuki T, Bies RR, Remington G, Pollock BG, Mimura M, Uchida H. Challenging the need for sustained blockade of dopamine D2 receptors estimated from antipsychotic plasma levels in the maintenance treatment of schizophrenia: a single-‐blind, randomized, controlled trial. Schizoph Res 164(1-‐3):149-‐154, 2015
314. Lee J, Fervaha G, Takeuchi H, Powell V, Remington G. Positive symptoms are associated with clincians’ global impression in treatment-‐resistant schizophrenia. J Clin Psychopharmacol 35(3):237-‐241, 2015
315. Spadaro A, Kellar J, Remington G, Sproule B, Al-‐Sukhni M, Chaiet A. Development and evaluation of an educational program for clinical pharmacists to conduct standardized assessments for medication-‐induced movement disorders. Can J Hosp Pharm 68(3):258-‐264, 2015
316. Takeuchi H, Suzuki T, Remington G, Uchida H. Antipsychotic polypharmacy and corrected QT interval: a systematic review. Can J Psychiatry 60(5):215-‐222, 2015
317. Fervaha G, Foussias G, Agid O, Remington G. Motivational deficits in early schizophrenia: prevalent, persistent, and key determinants of functional outcome. Schizophr Res 166:9-‐16, 2015
318. Fervaha G, Hill C, Agid O, Takeuchi H, Foussias G, Siddiqui I, Kern RS, Remington G. Examination of the validity of the Brief Neurocognitive Assessment (BNA) for schizophrenia. Schizophr Res 166:304-‐309, 2015
319. Fervaha G, Siddiqui I, Foussias G, Agid O, Remington G. Motivation and cognition in patients with schizophrenia. J Int Neuropsychol Soc 21:436-‐443, 2015
25
320. Hettige N, Hazra M, Borlido C, Zai C, Kennedy JL, Strauss J, Remington G, De Luca V. Use of candidate gene markers to guide antipsychotic dosage adjustment. Prog Neuropsychopharmacol Biol Psychiatry 2014 July 9 [Epub ahead of print]
321. Gerretsen P, Menon M, Chakravarty MM, Lerch JP, Mamo DC, Remington G, Pollock BG, Graff-‐Guerrero A. Illness denial in schizophrenia spectrum disorders: a structural and functional MRI study, Hum Brain Mapp 2014 Sept 11 [Epub ahead of print]
322. Fervaha G, Takeuchi H, Agid O, Lee J, Foussias G, Remington G. Determinants of patient-‐rated and clinician-‐rated illness severity in schizophrenia. J Clin Psychiatry, 2014 Dec 23 [Epub ahead of print]
323. Strassnig M, Clarke J, Mann S, Remington G, Ganguli R. Body composition, pre-‐diabetes and cardiovascular disease risk in early schizophrenia. Early Interv Psychiatry 2015 Mar 10 [Epub ahead of print]
324. Rajji TK, Mulsant BH, Davies S, Kalache SM, Tsoutsoulas C, Pollock BG, Remington G. Prediction of working memory performance in schizophrenia by plasma ration of clozapine to N-‐desmethylclozapine, Am J Psychiatry 2015 Apr 10 [Epub ahead of print]
325. Foussias G, Siddiqui I, Fervaha G, Mann S, McDonald K, Agid O, Zakzanis KK, Remington G. Motivated to do well: an examination of the relationship between motivation, effort, and cognitive performance in schizophrenia. Schizophr Res 2015 May 22 [Epub ahead of print]
326. Caravaggio F, Hahn M, Nakajima S, Gerretsen P, Remington G, Gragg-‐Guerrero A. Reduced insulin receptor-‐mediated modulation of striatal dopamine release by basal insulin as a possible contributing factor to hyperdopaminergia in schizophrenia. Med Hypotheses 2015 June 24 [Epub ahead of print]
327. Lockwood J, Remington G. Emerging drugs for antipsychotic-‐induced tardive dyskinesia: investigational drugs in phase II and III clinical trials. Expert Opin Emerging Drugs 2015 July 13:1-‐15 [Epub ahead of print]
328. Fervaha G, Duncan M, Foussias G, Agid O, Faulkner GE, Remington G. Effort-‐based decision making as an objective paradigm for the assessment of motivational deficits in schizophrenia. Schizxophr Res 2015 July 4 [Epub ahead of print]
329. Fervaha G, Agid O, Foussias G, Siddiqui I, Takeuchi H, Remington G. Neuocognitive impairment in the deficit subtype of schizophrenia. Eur Arch Psychiatry Clin Neurosci 2015 Aug 11 [Epub ahead of print]
330. Remington G, Seeman MV. Schizophrenia and the influence of male gender. Clin Pharmacol Ther 2015 Aug 11 [Epub ahead of print]
331. Fervaha G, Agid O, Takeuchi H, Foussias G, Remington G. Effect of antipsychotic medication on overall life satisfaction among individuals with chronic schizophrenia: Findings from the NIMH CATIE study. Eur Neuropsychopharmacol, accepted
26
332. Fervaha G, Zakzanis KK, Jeffay E, Graff-‐Guerrero A, Foussias G, Agid O, Remington G. Amotivation as central to negative schizotypy and their predictive value for happiness. Pers Indiv Dif, accepted
333. Plitman E, Nakajima S, de la Fuente-‐Sandoval C, Gerretsen P, Chakravarty M, Kobylianskii J, Chung JK, Caravaggi F, Iwata Y, Remington G, Graff-‐Guerrero A. Glutamate-‐mediated exictotoxicity in schizophrenia: a revew. Eur Neuropsychopharmacol, accepted
334. Lee J, Bies R, Bhaloo A, Powell V, Remington G. Clozapine and anemia: a 2-‐year follow-‐up study. J Clin Psychopharmacology, accepted
335. Borlido C, Remington G, Graff A, Atenovich T, Hazra M, Wong A, Daskalakis ZJ, Mamo D. Reducing antipsychotic polypharmacy to monotherapy in schizophrenia: a randomized, double-‐blind, placebo-‐controlled study. J Clin Psychiatry, accepted
336. Lee J, Takeuchi H, Fervaha G, Foussias G, Agid O, Farooq S, Remington G. Subtyping schizophrenia by treatment response: antipsychotic development and the central role of positive symptoms. Can J Psychiatry, accepted
337. Lee J, Bies R, takeuchi H, Fervaha G, Bhaloo A, Remington G. Qunatifying intraindividual variations in plasma clozapine levels: a population pharmacokinetic approach. J Clin Psychiatry, accepted
(b) PUBLISHED REVIEWS OF MANUSCRIPTS
1. Faulkner G, Cohn T, Remington G. Interventions to reduce weight gain in schizophrenia. Cochrane Database Syst Rev 24(1):CD005148, 2007. Reviewed in Schizophr Bull 33:654-‐656, 2007
2. Foussias G, Remington G. Antipsychotics and schizophrenia: from efficacy and effectiveness to clinical decision-‐making. Can J Psychiatry 55:117-‐125, 2010. Reviewed in: Psychiatry Drug Alerts 4:26, 2010
A.2. Non-‐Refereed Publications
(a) CHAPTERS
1. Remington G, Sloman L. Neurotransmitters, psychopathology and central nervous system development. In: MacLeod SM, Radde IC, eds. Pediatric Clinical Pharmacology. St. Louis, Mosby Yearbook Publishers, 1993, pp 137-‐153
2. Sloman L, Remington G. Pediatric psychopharmacology: clinical guidelines. In: MacLead SM, Radde IC, eds. Pediatric Clinical Pharmacology. St. Louis, Mosby Yearbook Publishers, 1993, pp 384-‐404
3. Remington G, Adams M. Depot neuroleptics. In: Ancill R, Holliday S, Higenbottam J, eds. Schizophrenia: Exploring the Spectrum of Psychosis. Chichester: Wiley & Sons, 1994, pp 171-‐204
27
4. Remington G. Dopaminergic and serotonergic mechanisms in the action of standard and atypical neuroleptics. In: Shriqui CL, Nasrallah HA, eds, Contemporary Issues in the Treatment of Schizophrenia. Washington DC, American Psychiatric Press, 1995, pp 295-‐328
5. Remington G. Neuroleptics. In: Baskys A, Remington G, eds. Brain Mechanisms and Psychotropic Drugs. Boca Raton, CRC Press, 1996, pp 193-‐211
6. Baskys A, Remington G. Serotonin and dopamine. In: Baskys A, Remington G, eds. Brain Mechanisms and Psychotropic Drugs. Boca Raton, CRC Press, 1996, pp 55-‐71
7. Kapur S, Remington G. Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia. In: Caskey CT, ed. Annual Review of Medicine: Selected Topics in the Clinical Sciences, Volume 52. Palo Alto, Annual Reviews, 2001, pp 503-‐517
8. Remington G, Kapur S, Zipursky B. Pharmacotherapy of first episode psychosis. In: Miller T, Mednick SA, McGlashan TH, Libiger J, Johannessen, eds. Early Intervention In Psychiatric Disorders. Dordrecht, Kluwer Academic Publishers, 2001, pp 167-‐180
9. Bezchlibnyk-‐Butler KZ, Jeffries JJ, Remington G. Antipsychotics (Neuroleptics). In: Bezchlibnyk-‐Butler KZ, Jeffries JJ, eds. Clinical Handbook of Psychotropic Drugs, 11th ed. Toronto, Hogrefe & Huber, 2001, pp 64-‐106
10. Remington G, Kapur S, Zipursky R. Antipsychotic side effects: assessment, treatment, and prevention. In: Csernansky J, ed. Schizophrenia: A New Guide for Clinicians. New York: Marcel Dekker, 2002, pp 213-‐245
11. Waddington JL, Kapur S, Remington G. The clinical psychopharmacology of first-‐ and second-‐generation antipsychotic drugs in schizophrenia. In: Hirsch S, Weinberger D, eds. Schizophrenia. Oxford: Blackwell, 2003, pp 421-‐441
12. Remington G (chapter co-‐editor). Antipsychotics (neuroleptics). In: Bezchlibnyk-‐Butler K, Jeffries JJ, eds. Clinical Handbook of Psychotropic Drugs, 15th ed. Gottingen: Hogrefe & Huber, 2005, pp 73-‐119
13. Remington G, Kapur S. The pharmacology of typical and atypical antipsychotics. In: Factor S, Lang AE, Weiner WJ, eds. Drug Induced Movement Disorders. Malden: Blackwell Futura, 2005, pp 55-‐71
14. Remington G. Alterations of dopamine and serotonin transmission in schizophrenia. In: Di Giovanni G, Di Matteo V, Esposito E, eds. Serotonin-‐Dopamine Interaction: Experimental and Therapeutic Relevance. Amsterdam, Elsevier, 2008, pp 117-‐140
15. Waddington JL, O’Tuathaigh CMP. Remington GJ. Second generation antipsychotics: mechanistically distinct or minor variants? In: Mortimer A, McKenna P, eds. Therapeutic Strategies in Schizophrenia. Oxford: Clinical Publishing, 2010, pp 207-‐215
28
16. Remington G. Augmenting clozapine response in treatment-‐resistant schizophrenia. In: Elkis H, Meltzer HY, eds. Therapy-‐Resistant Schizophrenia. Basel, Karger, 2010, pp 129-‐151
17. Remington G. Second and third generation antipsychotics. In, Stolerman I, ed. Encyclopedia of Psychopharmacology, Part 19. Heidelberg: Springer-‐Verlag, 2010, pp 1187-‐1192
18. Waddington JL, O’Tuathaigh CMP, Remington GJ. The pharmacology and neuroscience of antipsychotic drugs. In: Weinberger D, Harrison P, eds. Schizophrenia. Oxford: Blackwell, 2011, pp 485-‐514
19. Foussias G, Agid O, Remington G. Negative symptoms across the schizophrenia spectrum: phenomenological and neurobiological perspectives. In, Ritsner MS, ed. Handbook of Schizophrenia Spectrum Disorders, Vol. II: Phenotypic and Endophenotypic Presentations. Dordecht: Springer-‐Science+Business Media, BV, 2011, pp 1-‐32
(b) BOOKS
1. Baskys A, Remington G (eds). Brain Mechanisms and Psychotropic Drugs. Boca Raton, CRC Press, 1996
(c) BOOK REVIEWS
1. Lithium Treatment of Manic-‐Depressive Illness (2nd ed), Schou M, 1983. Can Med Assoc J, 1984.
2. Handbook of Psychopharmacology, Iversen LL, Iversen SD, Snyder SH (Eds), 1984. Can J Psychiatry, 32:410-‐411, 1987
3. Human Psychopharmacology: Measures and Methods (Vol 1), Hindmarch I, Stonier PD, 1987. Can Pharm J, 121:125-‐126, 1988
4. Psychopharmacology of Antipsychotics and Psychopharmacology of Antidepressants, Stahl SM, 1999. Am J Psychiatry, 158:1538, 2001
(d) OTHER REVIEWS/REPORTS/CONSENSUS GUIDELINES
1. Remington G. Zotepine was as effective as typical and other atypical antipsychotics and more effective than schizophrenia in schizophrenia (commentary). Evid Based Ment Health, 3:78, 2000
2. Remington G. Intramuscular ziprasidone reduced symptoms and was well tolerated in acute psychosis (commentary). Evid Based Ment Health, 4:74, 2001
3. Remington G, Kapur S. Amisulpride is effective and safe in schizophrenia (commentary). Evid Based Ment Health, 5:85, 2002
29
4. Remington G (Expert Panel). Expert Consensus Guidelines: optimizing pharmacological treatment for psychotic disorders. J Clin Psychiatry 64(Suppl 12):4-‐100, 2003
5. Remington G. Aripiprazole in augmentation in clozapine-‐treated patients with refractory schizophrenia: an 8-‐week, randomized, double-‐blind, placebo-‐controlled trial (commentary). Evid Based Ment Health, 12:51, 2009
6. Sockalingam S, Remington G. Review: insufficient evidence to guide use of drugs for clozapine induced hypersalivation (commentary). Evid Based Ment Health, 12:12, 2009
7. Remington G (Expert Consultant). Treatment Guidelines: Drugs for psychotic disorders. The Medical Letter, 8(96), 2010
8. Remington G (Expert Panel). International consensus study of antipsychotic dosing. Am J Psychiatry, 167:686-‐693, 2010
9. Agid O, Remington G. Review: maintenance antipsychotics prevent relapse in patients with schizophrenia (commentary). Evid Based Ment Health, 15:92, 2012
(e) GOVERNMENT REPORTS
1. Atypical antipsychotics for schizophrenia: combination therapy and high doses [Internet]. Ontarion (ON). Canadian Agency for Drugs and Technologies in Health; 2011 Dec.
2. Lurasidone hydrochloride (Latuda): Management of manifestations of schizophrenia. Ontario (ON). Canadian Agency for Drugs and Technologies in Health; 2014 Jan.
(f) PUBLISHED ABSTRACTS
1. Kapur S, Remington G, Jones C, Roy P, Reed K, Houle S, Zipursky RB. What is the lowest effective dose of haloperidol? Evidence from PET studies. Biol Psychiatry 39:513, 1996
2. Remington G. First episode psychosis: diagnosis, treatment and the role of new antipsychotics. Eur Neuropsychopharmacol 6(suppl 3):33, 1996
3. Remington G. Medication choices in the maintenance of neuroleptic therapy: theory and clinical practice. Eur Neuropsychopharmacol 6(suppl 3):85, 1996
4. Kapur S, Remington GJ, Jones C, Houle S, Zipursky RB. Is loxapine an atypical antipsychotic: a PET study of the in vivo 5-‐HT2 and D2 occupancy. Eur Neuropsychopharmacol 6(suppl 3):72, 1996
30
5. Kapur S, Remington GJ, Jones C, Roy P, Reed K, Houle S, Zipursky RB. Relationship between D2 occupancy and plasma haloperidol. A PET study. Eur Neuropsychopharmacol 6(suppl 3):73, 1996
6. Remington G, Kapur S, Jones C, Zipursky RB, Houle S. Risperidone and the relationship between D2 receptor occupancy and plasma levels. Eur Neuropsychopharmacol 6(suppl 3):74, 1996
7. Zipursky RB, Kapur S, Jones C, Remington G, Shammi C, Houle S. Is there a ‘glass ceiling’ to the D2 occupancy of clozapine? J Clin Psychopharmacol 11:A73, 1997
8. Remington G, Khramov I, Coulter K, Arndt M, Health service utilization comparing clozapine, risperidone and depot neuroleptics: a 2-‐year follow-‐up study. Int J Neuropscyhopharmacol 2(suppl 1):S102, 1998
9. Kapur S, Jones C, Remington G, Zipursky RB. Relationship between dose and D2 occupancy of typical and at atypical antipsychotics – implications for comparison. Int J Neuropscyhopharmacol 2(suppl 1):S63, 1998
10. Basile V, Masellis M, Paterson AD, Meltzer HY, Lieberman JA, Potkin S, Remington G, Kennedy JL. Is variation in the dopamine D3 receptor gene associated with tardive dyskinesia? Am J Med Genet 81(6): Erratum 573, Abstract # 57A, 1998
11. Fitzgerald PB, Kapur S, Zipursky RB, Jones C, Remington G. The prediction of haloperidol binding to central dopamine D2 receptors from plasma levels: A PET study. Schizophr Res 36:220, 1999
12. Jones C. Kapur S, Zipursky RB, Remington G, Shammi CM, Houle S. Antipsychotic action with low D2 occupancy: a study of quetiapine. Schizophr Res 36:242, 1999
13. Kapur S, Remington GJ, Jones C, Zipursky RB. Does dopamine D2 occupancy predict antipsychotic response and side effects? A randomized double-‐blind test of the hypothesis. Schizophr Res 36:242, 1999
14. Silvestri S, Seeman MV, Negrete JC, Houle S, Shammi CM, Remington G, Kapur S, Zipursky RB, Wilson A, Christensen BK, Seeman P. Dopamine D2 upregulation and 5-‐HT2 downregulation measured after neuroleptic withdrawal using PET. Schizophr Res 36:247, 1999
15. Remington G, Shammi C, Sethna R. Antipsychotic dosing patterns in 3 treatment settings. Schizophr Res 36:293, 1999
16. Collins A, Remington G. The contribution of insight, psychopathological symptoms, and neurocognitive function to quality of life in schizophrenia. Schizophr Res 36:324, 1999
17. Basile V, Masellis M, Paterson AD, Meltzer HY, Lieberman HA, Potkin S, Remington G, Kennedy JL. Dopamine system genes: is DRD3 a putative risk factor for tardive dyskinesia. Schizophr Res 36:361, 1999
31
18. Silvestri S, Seeman MV, Negrete JC, Houle S, Shammi CM, Remington GJ, Kapur S, Zipursky RB, Wilson A, Christensen BK, Seeman P. Increase in dopamine D2 receptor binding following long-‐term treatment with neuroleptics in humans. Schizophr Res 41:237-‐238, 2000
19. Kapur S, Wadenberg M-‐L, Remington G. Are animal studies of antipsychotics appropriately dosed? Lessons from bedside to bench. Biol Psychiatry 47:16S, 2000
20. Jones C, Kapur S, Remington G, Zipursky RB. Transient D2 dopamine receptor occupancy in low EPS-‐incidence drugs: PET evidence. Biol Psychiatry 47:112S, 2000
21. Kapur S, Zipursky R, Remington G, Seeman P. Fast Kd at the dopamine D2 receptor (not high affinity at other receptors) is the key to clozapine’s uniqueness and atypical antipsychotic activity. Int J Neuropsychopharmacol 3(suppl 1):S95, 2000
22. Kapur S, Lewis R, Verhoeff NPLG, Jones C, Remington G, Zipursky R. PET studies of serotonin receptors in schizophrenia: implications for pathophysiology and treatment. Int J Neuropsychopharmacol 3(suppl 1):S14, 2000
23. Kwon J, Collins A, Christensen B, Remington G. Medication compliance in patients with schizophrenia taking oral antipsychotics. Int J Neuropsychopharmacol 3(suppl 1):S124-‐S125, 2000
24. Cohn T, Remington G. Changing times, changing concerns – a cross-‐sectional study of antipsychotic medication use and cardiac risk factors in 213 long-‐term psychiatric inpatients. Int J Neuropsychopharmacol 3(suppl 1):S153, 2000
25. Cohn T, Miles J, Blake H, Achtenberg R, Boudreau R, Challis G, Kemp K, Preston S, Remington G. A novel weight management program for young adults at risk for antipsychotic-‐induced weight gain. Int J Neuropsychopharmacol 3(suppl 1):S153-‐S154, 2000
26. Waerner T, Bassi M, Dubuis J, Fleischhacker WW, Kissling W, Linszen D, Remington G, Turner T, Psykiatrin WM. An international survey on information needs of patients with schizophrenia and their carers and of patient management issues. Int J Neuropsychopharmacol 2(suppl 1):S117, 2000
27. Waerner T, Bassi M, Dubuis J, Fleischhacker WW, Kissling W, Linszen D, Remington G, Turner T, Psykiatrin WM. An international survey on information needs of patients with schizophrenia and their carers and of patient management issues. Eur Neuropsychopharmacol 10(suppl 3):S297, 2000
28. Millikin C, Christensen BK, Remington G, Shammi CM. Cognitive effects of clozapine treatment: the role of motor functioning. J Int Neuropsych Soc 7:163, 2001
29. Kapur S, Seeman P, Zipursky RB, Remington GJ. Fast dissociation from the dopamine D2 receptor (not high affinity at multiple receptors) is the key to “atypical” antipsychotics. Schizophr Res 49(suppl):92, 2001
32
30. Addington DE, Addington J, Patten S, Remington GJ, Moamai J, Labelle A. Sertraline for depression in remitted schizophrenia. Schizophr Res 49(suppl):219, 2001
31. Remington GJ, Kapur S, Shammi C, Seeman P. ‘Extended’ dosing as an alternative to ‘intermittent’ or ‘targeted’ antipsychotic therapy: rationale and pilot study. Schizophr Res 49(suppl):243, 2001
32. Collins AA, Kwon J, Christensen BK, Remington GJ. The clinical correlates of insight in schizophrenia. Schizophr Res 49(suppl):258, 2001
33. Cohn TA, Remington GJ. Risk factors for coronary vascular disease in long-‐term psychiatric inpatients on typical and atypical antipsychotic medications. Schizophr Res 49(suppl):282, 2001
34. Dickson RA, Violata C, Smekal T, Glazer WM, Remington G, Stip E, Walker DJ, Jones B. Serial measurement of sexual function in an open-‐label olanzapine switch trial. Schizophr Res 53(suppl):167, 2002
35. Kraljevic I, MacKeigan L, Einarson T, Remington G. Cost analysis of depot dosage forms of atypical versus typical antipsychotics. Value in Health 5(3):236, 2002
36. Turrone P, Remington G, Nobrega JN, Kapur S. Haloperidol-‐induced dopamine D2 receptor occupancy and vacuous chewing movements in a rat model of tardive dyskinesia. Schizophr Res 51(suppl):82, 2002
37. Remington G, Roy P, Shammi C, Hiscox W, Kapur S. Haloperidol augmentation of clozapine partial responders. Int J Neuropsychopharmacol 5(suppl 1): S75, 2002
38. Cohn T, Kameh H, Ghatavi K, Remington G. A pilot program to modify diet and activity in patients on clozapine: lessons learned. Int J Neuropsychopharmacol 5(suppl 1): S170, 2002
39. Cohn T, Wolever T, Zipursky R, Kameh H, Remington G. Screening for diabetes and impaired glucose tolerance in patients on antipsychotic medication. Int J Neuropsychopharmacol 5(suppl 1): S168, 2002
40. Cohn T, Kameh H, Ghatavi K, Remington G. A pilot program to modify diet and activity in patients on clozapine: lessons learned. Int J Neuropsychopharmacol 5(suppl 1): S170, 2002
41. Stip E, Remington G, Durson SM, Reiss JP, MacEwan GW, Chokka PR, Dickson RA, Jones B. Canadian multi-‐center trial assessing memory and executive function in patients with schizophrenia spectrum disorders treated with olanzapine. Int J Neuropsychopharmacol 5(suppl 1): S79, 2002
42. Remington G, Devos E, Eerdekens , Duchesne I, Leaf A, Mehnert A. Treatment with long-‐acting risperidone injection reduces healthcare resource use. Int J Neuropsychopharmacol 5(suppl 1): S189, 2002
33
43. Remington G. Rational psychopharmacology in early psychosis. Acta Psychiatr Scand 106: 32-‐33, 2002
44. Remington G. An educational intervention to enhance treatment adherence in early schizophrenia. Acta Psychiatr Scand 106: 49, 2002
45. Remington G, Kapur S, Shammi C, Seeman P. Is daily antipsychotic dosing necessary? Acta Psychiatr Scand 106: 47, 2002.
46. Jensen J, McIntosh R, Crawley AP, Mikulis DJ, Remington G, Kapur S. An fMRI paradigm to study responses to aversive stimuli – a central role for limbic striatum. Schizophr Res 2003; 60 (suppl): 224
47. Dickson RA, Glazer WM, Remington GJ, Stip E, Walker DJ, Luther M, Jones B. Perceptions of sexual functioning, prolactin levels and psychopathology in an olanzapine switch trial. Schizophr Res 2003; 60 (suppl): 281
48. Remington G, Light M, Lasser R, Bossie C, Zhu Y, Gharabawi G. Can stable patients with schizophrenia improve? The impact of partial compliance versus constant therapy. Schizophr Res 2003; 60 (suppl): 300
49. Collins A, Remington GJ. An educational intervention designed to improve treatment adherence in schizophrenia. Schizophr Res 2003; 60 (suppl): 321
50. Cohn T, Remington G. Risk factors for coronary heart disease in longer-‐term patients on antipsychotic medication: high prevalence of syndrome X. Schizophr Res 2003; 60 (suppl): 353
51. Kiang M, Daskalakis ZJ, Christensen BK, Remington G, Kapur S. Actigraphic measurement of single-‐dose haloperidol and olanzapine on spontaneous motor activity in normal subjects. Schizophr Res 2003; 60 (suppl): 358
52. Turrone P, Remington G, Kapur S, Nobrega J. Differential effects of sustained versus transient dopamine D2 receptor occupancy in the development of vacuous chewing movements in rats. Schizophr Res 2003; 60 (suppl): 368
53. Turrone P, Remington G, Kapur S, Nobrega J. The effects of sustained versus transient dopamine D2 occupancy in the development of vacuous chewing movements (VCMs) in rats. Biol Psyhciatry 2003; 53 (suppl): 81S
54. Mamo DC, Kapur S, Shammi CM, Papatheodorou G, Mann S, Remington G. Dopamine D2-‐ and serotonin 5-‐HT2-‐receptor occupancy at therapeutic doses of ziprasidone: a PET study. Biol Psychiatry 2003; 55(suppl): 40S
55. Tauscher J, Remington G, Zipursky RB, Kapur S. Serial PET imaging of dopamine D2 and serotonin 5-‐HT2A receptors reveals prolonged brain kinetics of antipsychotics. Biol Psychiatry 2003; 55(suppl): 91S
56. Turrone P, Remington G, Kapur S, Nobrega J. Continuous D2 receptor occupancy with olanzapine also induces vacuous chewing movements (VCMs) in rats. Biol Psychiatry 2003; 55(suppl): 143S
34
57. Mizrahi R, Mamo DC, Remington G, Zipursky RB, Kapur S. How antipsychotics work: a phenomenological hypothesis. Biol Psychiatry 2003; 55(suppl): 174S
58. Remington G. Optimizing the maintenance treatment of schizophrenia. Int J Neuropsychopharmacol 2004; 7(suppl 1): S27
59. Mizrahi R, Mamo D, Remington G, Zipursky R, Kapur S. A novel instrument to assess delusions form a dimensional perspective. Int J Neuropsychopharmacol 2004; 7(suppl 1): S221
60. De Luca V, Muller DJ, Basile VS, Hwang R, Masellis M, Shinikai T, Remington G, Meltzer H. Kennedy JL. Dopamine beta hydroxylase polymorphism: association with ethnicity but not with tardive dyskinesia. Int J Neuropsychopharmacol 2004; 7(suppl 1): S410
61. Mamo D, Shammi C, Papatheodorou G, Mann S, Kapur S, Remington G. Dopamine D2 and Serotonin 5-‐HT2 receptor occupancy at therapeutic doses of ziprasidone: a PET study. Int J Neuropsychoparmacol 2004; 7(suppl 1): S414
62. Cohn TA, Greenwood CE, Remington G. Body composition, physical activity and diet in patients with schizophrenia and related disorders under antipsychotic treatment. Int J Neuropsychopharmacol 2004; 7(suppl 1):S426
63. Remington G, Mamo D, Shammi C, Papatheodorou G, Therrien F, Mann S, Kapur S. Dopamine D2 and serotonin 5-‐HT2 receptor occupancy at therapeutic doses of ziprasidone: a PET study. Schizophr Res 2004; 70(suppl): 13
64. Collins A, Remington G. An educational intervention designed to improve treatment adherence in first-‐episode schizophrenia. Schizophr Res 2004; 70(suppl): 92
65. Cohn TA, Wolever T, Bois D, Zipursky RB, Remington G. First episode and neuroleptic free patients with schizophrenia have reduced insulin sensitivity: a minimal model analysis. Schizophr Bull 2005; 31: 197-‐198
66. De Luca V, Remington G, Meltzer HY, Lieberman JA, Potkin SG, Kennedy JL. New candidate genes in tardive dyskinesia: interaction between drug transporter and transduction pathway. Schizophr Bull 2005; 31:267
67. Remington G, Mamo D, Labelle A, Re9iss J, Shammi C, Mann S, Mannaert E, Kapur S. Peak and trough dopamine D2 receptor occupancy for long-‐acting injectable risperidone: a PET study. Schizophr Bull 2005; 31: 444
68. Mizrahi R, Mamo D, Bagby R, Remington G, Zipursky R, Kapur S. Understanding how antipsychotics improve psychosis: a multidimensional perspective. Schizophr Bull 2005; 31: 497-‐498
69. Shammi C, Chung C, Remington G. Clinical symptoms and the prediction of clozapine response. Schizophr Bull 2005; 31: 503
70. Collins AA, Remington GJ. An educational intervention designed to improve treatment adherence in schizophrenia. Schizophr Bull 2005; 31: 522-‐523
35
71. Faulkner GE, Cohn T, Remington G. Validation of a physical activity assessment tool for individuals with schizophrenia. Schizophr Bull 2005; 31: 523-‐524
72. Saeedi H, Remington G, Christensen B. The impact of haloperidol, a DA D2 antagonist, on cognition and mood. Schizophr Bull 2005; 31: 569
73. Remington G, Mamo D, Labelle A, Reiss J, Shammi C, Mann S, Mannaert E, Kapur S. A PET study evaluating dopamine D2 receptor occupancy for long-‐acting injectable risperidone. Biol Psychiatry 2005; 57: 31S
74. Cohn TA, Remington G, Zipursky R, Wolever T. First episode and neuroleptic free patients with schizophrenia have reduced insulin sensitivity: a minimal model analysis. Biol Psychiatry 2005; 57: 80S
75. Cohn TA, Bois D, Remington G. Topiramate added to clozapine – metabolic effects, antipsychotic augmentation, safety and tolerability: a 12-‐week open study. Biol Psychiatry 2005; 57: 92S-‐93S
76. Remington G, Mamo D, Labelle A, Re9iss J, Shammi C, Mann S, Mannaert E, Kapur S. Peak and trough dopamine D2 receptor occupancy for long-‐acting injectable risperidone: a PET study. Eur Neuropsychopharmacol 2005 (suppl 3): S461
77. Zai CC, Deluca V, Muller D, Remington G, Meltzer HY, Lieberman JA, Potkin SG, Kennedy JL. Association of a polymorphism 5’ of the dopamine receptor DRD3 gene in schizophrenic Caucasians with tardive dyskinesia. Biol Psychiatry 2006 59(8S): 30S-‐31S
78. Chintoh A, Mann S, Lam L, Lam T, Naasan A, Remington G, Giacca A. Insulin resistance following olanzapine administration. Int J Neuropsychopharmacol 2006; 9(suppl 1): S144
79. Agid O, Kapur S, Remington G, Zipursky RB. Clozapine for first-‐episode schizophrenia patients with persisting positive symptoms. Schizophr Bull 2007; 33: 417
80. Chintoh A, Mann S, Lam L, Tyagi Kumar N, Giacca A, Fletcher P, Nobrega J, Remington G. Immediate changes in insulin resistance and secretion following olanzapine administration. Schizophr Bull 2007; 33: 495
81. Cohn TA, Remington G, Cohn J. Metabolic monitoring for clozapine treated patients. Schizophr Bull 2007; 33: 496
82. Mann S, Chintoh A, Giacca A, Cohn T, Fletcher P, Nobrega J, Remington G. The effects of olanzapine on weight gain and locomotor activity: an animal model. Schizophr Bull 2007; 33: 502
83. Zai C, De Lucca V, Muller DJ, Remington G, Meltzer HY, Lieberman JA, Potkin SG, Kennedy JL. Association of a polymorphism upstream of dopamine receptor DRD3 gene with tardive dyskinesia. Schizophr Bull 2007; 33: 508
36
84. Kennedy JL, Muller DJ, Hwang R, Zai C, Romano-‐Silvo MA, Cohn T, Remington G. Pharmacogenetics of antipsychotic drug response and side effects in schizophrenia. Biol Psychiatry 2007; 61(8S): 106S
85. Zai CC, Renou J, De Luca V, Mueller DJ, Remington G, Meltzer HY, Lieberman JA, Potkin SG, Le Foll B, Kennedy JL. Association of brain derived growth factor (BDNF) and dopamine receptor DRD3 gene polymorphisms, as well as their interaction in schizophrenia patients and tardive dyskinesia Biol Psychiatry 2007; 61(8S): 188S
86. Foussias G, Mann S, Remington G. A phenomenological study of negative symptoms in schizophrenia: amotivation and its relationship to functioning. Schizophr Bull 2009; 35(Suppl 1): 13-‐14
87. Zai CC, Tiwari AK, Basile V, De Luca V, Mueller DJ, Voineskos AN, Remington G, Meltzer HY, Lieberman JA, Potkin SG, Kennedy JL. MNSOD in tardive dyskinesia: gene association study and meta-‐analysis. Schizophr Bull 2009; 35(Suppl 1): 101
88. Tiwari AK, Zai CC, Mueller DJ, Remington G, Meltzer HY, Lieberman JA, Potkin SG, Kennedy JL. Lack of association of the NAD(P)H dehydrogenase quinine 1(NQO1) gene to tardive dyskinesia in chronic schizophrenia patients. Schizophr Bull 2009; 35(Suppl 1): 101-‐102
89. Souza RP, Romano-‐Silva MA, Lieberman JA, Meltzer HY, Zhen M, Remington G, Kennedy JL, Wong AH. Family-‐based association study of NALCN gene with schizophrenia. Schizophr Bull 2009; 35(Suppl 1): 125
90. Remington G, Mann S, Kapur S, Seeman P. ‘Extended’ dosing – redefining intermittent antipsychotic therapy: A double-‐blind trial. Schizophr Bull 2009; 35(Suppl 1): 351-‐352
91. Rajji T, Uchida H, Ismail Z, Ng W, Mamo D, Remington G, Pollock B, Mulsant B. Clozapine and global cognition in schizophrenia. Am J Geriatr Psychiatry 2010; 18 (Suppl 1): S65-‐S66
92. Foussias G, Mann S, Zakzanis KK, van Reekum R, Agid O, Remington G. Motivational deficits in schizophrenia: cross-‐sectional and longitudinal relationships with functioning. Schizoph Res 2010; 117: 303
93. Agid O, Arenovich T, Sajeev G, Ziursky RB, Kapur S, Remington G. Algorithm-‐based treatment of first-‐episode schizophrenia: response rates over three second generation antipsychotic trials. Schizoph Res 2010; 117: 373
94. Souza RP, Remington G, Meltzer HY, Lieberman JA, Potkin SG, Kennedy JL, Wong AH. Glial cell line-‐derived neurotrophic factor receptor alpha 2 is associated with tardive dyskinesia. Schizoph Res 2010; 117: 453
95. Agid O, Potkin S, Remington G, Kapur S, Vanderburg D, Watsky E, Siu C. Placebo response in antipsychotic trials: a systematic review and meta-‐analysis. Schizoph Res 2010; 117: 492
37
96. Potkin S, Agid O, Remington G, Kapur S, Watsky E, Vanderburg D, Siu C. Longitudinal trajectory analysis of placebo response: short-‐term and long-‐term randomized controlled trials. Schizoph Res 2010; 117: 496
97. Zai CC, Voineskos AN, Meltzer HY, Lieberman JA, Potkin SG, Remington G, Kennedy JL. GABA system genes in tardive dyskinesia. Biol Psychiatry 2010; 67: 166S.
98. Hahn M, Chintoh A, Mann S, Lam L, Giacca A, Fletcher P, and Remington G. Atypical
antipsychotics and effects of muscarinic and serotonergic receptor binding on insulin
secretion in vivo: an animal model. European J Neuropsychopharmacol 2010; 20 (Suppl 3): S517
99. Souza R, Remington G, Lieberman J, Meltzer HY, Kennedy JL. Is GSK-‐3B associated with tardive dyskinesia in schizophrenia subjects. Int J Neuropsychopharmacol 2010; 13 (Suppl): 206
100. Souza R, Remington G, Lieberman J, Meltzer HY, Kennedy JL. Prolactin association with tardive dyskinesia: an old hypothesis from a genetic perspective. Int J Neuropsychopharmacol 2010; 13 (Suppl): 206
101. Potkin S, Agid O, Remington G, Kapur S, Watsky E, McDonald K, Vanderburg D, Siu C. Placebo response in antipsychotic trials. Int J Neuropsychopharmacol 2010; 13 (Suppl): 234
102. Zai CC, de Luca A, Tiwari A, Mueller D, Freeman N, Voineskos A, Meltzer H, Lieberman J, Potkin S, Remington G, Kennedy JL. A pharmacogenetic study of the Huntington gene CAG repeat in schizophrenia. Int J Neuropsychopharmacol 2010; 13 (Suppl): 208
103. Hahn M, Chintoh A, Xu L, Lam L, Giacca A, Cohn T, Fletcher P, Mann S, Remington G. Atypical antipsychotics and effects of muscarinic, serotonergic, dopaminergic and histaminergic receptor binding on insulin secretion in vivo: an animal model. Int Clin Psychopharmacol 26: e146, September 2011 doi:10.1097/01.yic.0000405882.94837.86
104. Hahn MK, Chintoh A, Xu L, Mann S, Lam L, Giacca A, Cohn T, Fletcher P, Remington G. Atypical antipsychotics and effects of muscarinic, serotonergic, dopaminergic and histaminergic receptor binding on insulin secretion in vivo: an animal model. Schizophr Bull 2011; Suppl 1: 25-‐26
105. Zai C, Cowdhury N, Tiwari AK, deLuca V, Mueller DJ, Voineskos A, Meltzer HY, Lieberman J, Potkin SG, Remington G, Kennedy JL. Genetic association study of neuregulin and its receptor in tardive dyskinesia. Schizophr Bull 2011; Suppl 1: 79
106. Menon M, Caravaggio F, Graff A, Mamo DC, Remington G. The effects of oxytocin on brain activity during a “trust game” in schizophrenia. Schizophr Bull 2011; Suppl 1: 146-‐147
38
107. Gorczynski P, Faulkner G, Cohn T, Remington G, Leith L. Examining the efficacy and feasibility of exercise counselling in individuals with schizophrenia. Schizophr Bull 2011; Suppl 1: 265
108. Foussias G, Mann S, Zakzanis KK, van Reekum, Agid O, Remington G. Baseline motivational deficits as the key predictor of functioning in schizophrenia at 1-‐year follow-‐up. Schizophr Bull 2011; Suppl 1:265
109. Agid O, Siu C, Remington G, McDonald K, Watsky E, Vanderburg D, Potkin SG. Study quality assessment for placebo-‐controlled randomized trials in schizophrenia conducted 1966-‐2009. Schizophr Bull 2011; Suppl 1: 294
110. Suzuki T, Graff A, Uchida H, Caravagio F, De Luca V, Remington G, Mamo D. Transient dopamine D2 receptor occupancy of ziprasidone: a clinical 24-‐hour PET study. Biol Psychiatry 2011; 69: 261S-‐262S
111. Strassnig M, Mann S, Remington G, Ganguli R. Metabolic anticedents of insulin resistance in early schizophrenia. Biol Psychiatry 2011; 69:282S-‐283S
112. Hahn M, Chintoh A, Teo C, Mann S, Lam L, Fletcher P, Cohn T, Remington G, Giacca A. Intracerebroventricular olanzapine suppresses insulin secretion in a rat model. Eur Neuropyschopharmacol 2011; 21(S3):S472
113. Agid O, Siu C, Remington G, McDonald K, Watsky E, Vanderburg D, Potkin SG. Study quality assessment for placebo-‐controlled randomized trials in schizophrenia conducted 1966-‐2009. Eur Neuropyschopharmacol 2011; 21(S3):S421
114. Schizophr Bull 2011; Suppl 1: 294
115. Mizuno Y, Bies RR, Remington G, Mamo DC, Suzuki T, Pollock BG, Tsuboi T, Miniura M, Uchida H. Dopamine D2 receptor occupancy with risperidone or olanzapine needed for the maintenance treatment of schizophrenia: a cross-‐sectional study. Eur Arch Psychiatry Clin Neurosci 2011; 261 (Suppl 1): S56
116. Agid O, Siu C, Zipursky RB, Remington G. Time course of dropout rates in schizophrenia trials conducted from 1966 to 2010: a systematic review and meta-‐analysis. Neuropsychopharmacology 2011; 36 (Suppl 1):S103
117. Voineskos A, Foussias G, Lerch J, Lobaugh N, Remington G, Kennedy J Pollock B, Mulsant B. Subtyping schizophrenia using a multimodal neuroimaging approach. Neuropsychopharmacology 2011; 36 (Suppl 1):S280
118. Agid O, Siu CO, McDonald K, Tsoutsoullas C, Wass C, Foussias G, Remington G. Are patients with schizophrenia happy? Schizophr Res 2012; 136 (Suppl 1):S80
119. De Luca V, Zai C, Remington G, Kennedy JL. Effect of geographical ancestry on tardive dyskinesia. Schizophr Res 2012; 136 (Suppl 1):S122
120. Fervaha G, Teo C, Mann S, Hahn M, Foussias G, Agid O, Remington G. Examining levels of antipsychotic adherence to better undersand nonadherence in patients with schizophrenia. Schizophr Res 2012; 136 (Suppl 1):S161
39
121. Agid O, Siu CO, Zipursky RB, Remington G. Time course of dropout rates in schizophrenia trials conducted from 1966 to 2010: a systematic review and meta-‐analysis. Schizophr Res 2012; 136 (Suppl 1):S164
122. Guenette MD, Giacca A, Hahn M, Teo C, Lam L, Chintoh AF, Arenovich T, Remington G. Receptor binding profiles of antipsychotic medications and glucose dysregulation: an acute animal model. Schizophr Res 2012; 136 (Suppl 1):S189
123. Hahn M, Arenovich T, Wolever T, Giacca A, Cohn T, McIntyre R, Teo C, Clarke L, Powell V, Chintoh A, Mann S, Gomes S, Remington G. Single dose administration of olanzapine: effects on glucose metabolism, endocrine and inflammatory markers in healthy volunteers. Schizophr Res 2012; 136 (Suppl 1):S266
124. McCormick P, Fletcher P, Remington G. Effects of dopamine D3 stimulation on reward learning: implications for adjunct treatment of antipsychotic-‐induced motivational impairment. Schizophr Res 2012; 136 (Suppl 1):S356
125. Guenette MD, Giacca A, Hahn M, Teo C, Lam L, Chintoh AF, Arenovich T, Remington G. Receptor binding profiles of antipsychotic medications and glucose dysregulation: an acute animal model. Biol Psychiatry 2012; 71 (Suppl):41S-‐42S
126. Hahn M, Arenovich T, Wolever T, Giacca A, Cohn T, McIntyre R, Teo C, Clarke L, Powell V, Chintoh A, Mann S, Gomes S, Remington G. Single dose administration of olanzapine: effects on glucose metabolism in healthy volunteers. Biol Psychiatry 2012; 71 (Suppl):102S
127. Menon M, Gerretsen P, Schmitz TW, Anderson AK, Mamo DS, Korostil M, Remington G, Kapur S, Graff-‐Guerrero A. Self-‐referential abnormalities may be trait vulnerabilities for the development of delusions. Biol Psychiatry 2012; 71 (Suppl):252S
128. Ikai S, Remington G, Suzuki T, Tsuboi T, Hirano J, Tsunoda K, Nishimoto M, Watanabe K, Kitahata R, Mimura M. Dopamine D2 receptor occupancy with risperidone long-‐acting injectable during maintenance treatment in schizophrenia: a cross-‐sectional study. Int J Neuropsychopharmacol 2012; 15 (Suppl 1):51-‐52
129. Moriguchi S, Bies R, Remington G, Suzuki T, Mamo D, Mimura M, Pollock B, Uchida H. Dopamine D2 receptor occupancy and remission in schizophrenia: analysis of the CATIE data. Int J Neuropsychopharmacol 2012; 15 (Suppl 1):58
130. Suzuki T, Mulsant B, Uchida H, Mamo D, Tsunoda K, Watanabe K, Mimura M, Remington G. Defining treatment-‐resistant schizophrenia and treatment response: a pragmatic proposal. Int J Neuropsychopharmacol 2012; 15 (Suppl 1):136
131. Hahn MK, Chintoh A, Remington G, Teo C, Mann S, Arenovich T, Fletcher P, Guenette M, Cohn T, Giacca A. Insulin resistance and secretion in centrally-‐mediated antipsychotic effects in an animal model. Schizophr Bull 2013; (Suppl 1): S32
132. Menon M, Naber A, Caravaggio F, Gerretsen P, Zak PJ, Remington G, Graff-‐Guerrero A. The effects of oxytocin on brain activity during a ‘trust game’ in schizophrenia. Schizophr Bull 2013; (Suppl 1): S163
40
133. Foussias G, Siddiqui I, McDonald K, Hasan N, Thavabalasingam S, Plagiannakos C, ZawadzFoussias ki J, Zakzanis KK, Fletcher P, Wong A, Remington G. Evaluating motivation in schizophrenia in a virtual environment: a novel objective assessment methodology. Schizophr Bull 2013; (Suppl 1): S229
134. Zawadzki JA, Foussias G, Rodrigues A, Siddiqui I, Lerch J, Girrard T, Remington G, Grady C, Wong A. Spatial navigation in schizophrenia using a realistic virtual city. Schizophr Bull 2013; (Suppl 1): S254
135. Takeuchi H, Uchida H, Suzuki T, Bies RR, Watanabe K, Remington G, Mimura M. Effects of atypical antipsychotic dose reduction on cognitive function in stable patients with schizophrenia: a randomized controlled trial. Schizophr Bull 2013; (Suppl 1): S354
136. Hahn MK, Chintoh A, Remington G, Teo C, Mann S, Arenovich T, Fletcher P, Guenette M, Cohn T, Giacca A. Insulin resistance and secretion in vivo: centrally-‐mediated antipsychotic effects in an animal model. Biol Psychiatry 2013; 73(9S): 61S
137. Gerretsen P, Borlido C, Hassan S, Polsinelli G, Teo C, Mar W, Simon R, Menon M, Pothier DD, Rajji TK, Mulsant B, Deluca V, Ganguli R, Remington G, Pollock BG, Graff-‐Guerrero A. University of Toronto Insight into Psychosis scale (UTIP) – self report and AMP; rater versions: a novel, user friendly assessment tool for the measurement of insight into psychosis in schizophrenia spectrum disorders. Biol Psychiatry 2013; 73(9S): 208S
138. Fervaha G, Graff-‐Guerrero A, Zakzanis KK, Foussias G, Agid O, Remington G. Behavioural assessment of incentive motivation deficits in schizophrenia. Biol Psychiatry 2013; 73(9S): 276S
139. Mizrahi R, Addington J, Rusjan PM, Suridjan I, Ng A, Boileau I, Pruessner JC, Remington G, Houle S, Wilson AA. Exaggerated dopamine release in immigrants during social stress: a risk mechanism for psychosis. Schizophr Res 2014; 153(Suppl 1):S29
140. Agid O, Siu C, Remington G. Patterns of response and the neurobiology of relapse in schizophrenia. Schizophr Res 2014; 153(Suppl 1):S37
141. Hahn M, Remington G, Chintoh A, Teo C, Fletcher P, Nobrega J, Guenette M, Cohn T, Giacca A. Clinical insights derived from rodent models of antipsychotic-‐induced metabolic perturbations. Schizophr Res 2014; 153(Suppl 1):S70
142. Foussias G, Siddiqui I, McDonald K, Jeffay E, Zawadzki J, Wong A, Agid O, Zakzanis K, Remington G. Ecologically-‐valid assessment of attention in schizophrenia in a virtual environment. Schizophr Res 2014; 153(Suppl 1):S121
143. Siu C, Agid O, Waye M, Brambilla C, Choi W-‐K, Remington G, Harvey P. Insight into illness, cognitive reasoning and uncooperativeness in schizophrenia. Schizophr Res 2014; 153(Suppl 1):S125-‐S126
41
144. Agid O, Siu C, Harvey PD, Zipursky R, Fervaha G, Foussias G, McDonald K, Remington G. Treatment outcomes, insight and recovery in first-‐episode schizophrenia. Schizophr Res 2014; 153(Suppl 1):S165-‐S166
145. Takeuchi H, Fervaha G, Uchida H, Suzuki T, Bies R, Gronte D, Remington G. Is once daily dosing of perphenazine clinically feasible? Schizophr Res 2014; 153(Suppl 1):S180
146. Agid O, Fervaha G, Foussias G, Siu C, McDonald K, Remington G. The three faces of schizophrenia: subtyping schizophrenia based on response and implications for treatment. Schizophr Res 2014; 153(Suppl 1):S266-‐S267
147. Agid O, Fervaha G, McDonald K, Littrell R, Thoma J, Foussias G, Remington E, Siu C, Remington G. Value recalibration in first-‐episode schizophrenia. Schizophr Res 2014; 153(Suppl 1):S290
148. Fervaha G, Agid O, Foussias G, Graff-‐Guerrero A, Zakzanis K, Remington G. Behavioural economics of effort-‐based reward-‐driven choice in schizophrenia. Schizophr Res 2014; 153(Suppl 1):S315
149. Yoshida K, Bies R, Suzuki T, Remington G, Pollock B, Mizuno Y, Mimura M, Uchida H. Tardive dyskinesia in relation to dopamine D2 receptor occupancy in patients with schizophrenia: analysis of the CATIE data. Schizophr Res 2014; 153(Suppl 1):S383-‐S384
150. Wheeler A, Wessa M, Szeszko PR, Foussias G, Mallar Chakravarty M, Lerch JP, DeRosse P, Remington G, Mulsanr BH, Linke J, Malhotra AK, Voineskos A. Brain network investigation in schizophrenia, bipolar disorder and healthy controls reveals prominent network differences in deficit-‐subtype schizophrenia. Biol Psychiatry 2014 75(Suppl):106S
151. Fervaha G, Agid O, Foussias G, Graff-‐Guerrero A, Zakzanis KK, Remington G. Parsing motivational deficits in schizophrenia impairment in the computation of effort costs not reward value. Biol Psychiatry 2014 75(Suppl):206S
152. Hahn MK, Wilson V, Teo C, Chintoh A, Guenette M, Ahsan Z, Giacca A, Remington G. Metformin for attenuation of olanzapine-‐induced insulin resistance. Biol Psychiatry 2014 75(Suppl):210S
153. Carvaggio F, Nakajima S, Borlido C, Remington G, Gerretsen P, Wison A, Houle S, Menon M, Mamo D, Graff-‐Geurrero A. Estimating endogenous dopamine levels at D2 and D3 receptors in humans using the agonist radiotracer [11C]-‐(+)-‐PHNO. Biol Psychiatry 2014 75(Suppl):378S
154. Tsuboi T, Suzuki T, Bies RR, Remington G, Pollock BG, Hirano J, Mimura M, Uchida H. Is sustained dopamine D2 blockade above 65% necessary for maintenance treatment of schizophrenia? A single-‐blind, randomized, controlled study. Int J Neuropsychopharmacol 2014; 17(S1):103-‐104
155. Carvaggio F, Borlido C, Hahn M, Raitsin S, Plitman E, Nakajima S, Gerretsen P, Wilson A, Remington G, Graff-‐Guerrero A. Reduced insulin sensitivity is related to less endogenous dopamine at D2/D3 receptors in the ventral striatum of
42
healthy non obese humans: preliminary findings with [11C]-‐PHNO. Int J Neurosychopharmacol 2014; 17(S1):81-‐82
156. Takeuchi H, Fervaha G, Lee J, Agid O, Remington G. Impact of once-‐ versus twice-‐daily risperidone and olanzapine dosing on clinical outcomes: findings from the CATIE schizophrenia study. Int J Neuropsychopharmacol 2014; 17(S1):110-‐111
157. Siu C, Agid O, Waye M, Brambilla C, Choi WK, Remington G, Harvey P. Insight into illness and uncooperativeness in chronic schizophrenia. Int J Neuropsychopharmacol 2014; 17(S1):152-‐153
158. Siu C, Agid O, Waye M, Brambilla C, Choi WK, Remington G, Harvey P. Insight into illness and uncooperativeness in chronic schizophrenia. Eur Neuropsychopharmacol 2014; 24(Suppl 2):S544
159. Agid O, Siu C, Zipursky RB, Fervaha G, Foussias G, Remington G. Eur Neuropsychopharmaracol 2014; 24(Suppl 2):S560
160. Patel H, Gorczynski P, Faulkner G, Remington G, Ganguli R. Examining cardiorespiratory fitness in diabetic individuals with and without psychotic illness. Diabetes 2014; 63(Suppl 1):A587
161. Fervaha G, Foussias G, Agid O, Remington G. Reinforcement learning deficits in schizophrenia. Schizophr Bull 2015; 41(Suppl 1): S74
162. Siddiqui I, Foussias G, Fletcher P, Voineskos A, Fervaha G, Zakzanis K, Remington G. Novel objective assessment of exploratory behaviour and activity preference in schizophrenia using motion capture. Schizophr Bull 2015; 41(Suppl 1): S117-‐S118
163. Hahn M, Wilson V, Teo C, Chintoh A, Guenette M, Ahsan Z, Giacca A, Remington G. Metformin partially reverses olanzapine-‐induced glucose dysregulation. Schizophr Bull 2015; 41(Suppl 1): S127
164. Duncan MJ, Faulkner G, Remington G, Arbour-‐Nicitopoulos K. Characterizing affective responses to an acute bout of moderate-‐intensity exercise in people with schizophrenia. Schizophr Bull 2015; 41(Suppl 1): S168
165. Foussias G, Siddiqui I, Hawco G, Fervaha G, Saperia S, Zawadzki J, Lepage M, Zakzanis K, Aong AHC, Remington G. The neural correlates of effort valuation in a virtual environment in schizophrenia. Schizophr Bull 2015; 41(Suppl 1): S223
166. Caravaggio F, Borlido C, Wilson A, Houle S, Remington G, Kapur S, Graff-‐Guerrero A. Preliminary estimation of endogenous dopamine D2/3 receptors in medicated patients witwh schizophrenia using the agonist radiotracer [11C]-‐(+)-‐PHNO. Schizophr Bull 2015; 41(Suppl 1): S248
167. Plitman E, de la Fuente-‐Sandoval C, Leon-‐Ortiz P, Reyes-‐Madrigal F, Gomez-‐Cruz G, Nakajima S, Gerretsen P, Mallar Chakravarty M, Chavez S, Chung JK, Caravaggio F, Iwata Y, Uy D, Remington G, Graff-‐Guerrero A. Increased myo-‐inositol and choline levels within the associative striatum of antipsychotic-‐naïve patients with first-‐episode schizophrenia. Schizophr Bull 2015; 41(Suppl 1): S269
43
168. Tseng H-‐H, Kenk M, Remington G, Rusjan P, Wilson A, Prosser A, Houle S, Mizrahi R. Stress-‐induced dopamine release in subjects at clinical high risk for psychosis: preliminary results for a [11C]-‐FLB457 PET study. Schizophr Bull 2015; 41(Suppl 1): S277
169. Agid O, Siu C, Fervaha G, Foussias G, Remington G. Antipsychotic re-‐challenge in previous first episode schizophrenia responders. Schizophr Bull 2015; 41(Suppl 1): S299
170. Remington G, Lee J, Takeuchi H, Fervaha G, Foussias G, Agid O, Farooq S. Subtyping schizophrenia by treatment response: refining criteria. Schizophr Bull 2015; 41(Suppl 1): S330
171. Takeuchi H, Lee J, Fervaha G, Foussias G, Agid O, Remington G. Switching to clozapine using immediate vs. gradual antipsychotic discontinuation: a pilot, double-‐blind, randomized controlled trial. Schizophr Bull 2015; 41(Suppl 1): S335-‐S336
172. Tseng H-‐H, Kenk M, Remington G, Rusjan P, Wilson A, Houle S, Mizrahi R. Stress-‐induced prefrontal dopamine release in the early stages of psychosis: a preliminary report. Biol Psychiatry 2015; 77(9S): 118S-‐119S
173. Rao NP, Kenk M, Rusjan P, Suridjan I, Wilson A, Houle S, Strafella A, Remington G, Mizrahi R. Cortical dopaminergic deficiency in schizophrenia while performing a cognitive task. Biol Psychiatry 2015; 77(9S): 121S
174. Foussias G, Siddiqui I, Hawco C, Fervaha G, Saperia S, Zawadski J, Lepage M, Zakzanis KK, Wong AHC, Remington G. Investigation of effort valuation impairments in a virtual environment. Biol Psychiatry 2015; 77(9S): 184S
175. Siddiqui I, Fervaha G, Jeffay E, Zakzanis KK, Agid O, Remington G, Foussias G. Objective planning and executing gaol-‐directed behaviour in schizophrenia using a virtual environment. Biol Psychiatry 2015; 77(9S): 205S
176. Fervaha G, Agid O, Foussias G, Remington G. Feedback-‐driven trial-‐by-‐trial reward learning in schizophrenia. Biol Psychiatry 2015; 77(9S): 205S
177. Caravaggio F, Benarroch L, Teo C, Wilson V, Fletcher P, Remington G, Graff-‐Guerrero A, Hahn M. Acute central administration of insulin fails to modify amphetamine-‐induced changes in locomotor activity. Biol Psychiatry 2015; 77(9S): 259S
178. Takeuchi H, Fervaha G, Uchida H, Bies RR, Remington G. Antipsychotic drug plasma concentrations and amotivation in schizophrenia. Biol Psychiatry 2015; 77(9S): 269S
179. Behdinan T, Foussias G, Wheeler AL, Felsky D, Remington G, Rajji TK, Mallar Chakravarty M, Voineskos AN. Neuroimaging predictors of functional outcome in schizophrenia. Biol Psychiatry 2015; 77(9S): 357S
(f) OTHER PUBLICATIONS
44
1. Remington G. Sexual life events and schizophrenia (response). Compr Psychiatry 30:114, 1989
2. Remington G, Jeffries J. Neuroleptic-‐induce movement disorders. Psychiatry 3:52-‐55, 1989
3. Jeffries J, Remington G. Inpatient treatment of schizophrenia. Psychiatry 3:55-‐62, 1989
4. Remington G. Outpatient pharmacotherapy of schizophrenia. Drug Protocol 5:25-‐30, 1990
5. Remington G, Jeffries J. Pharmacologic management of schizophrenia. Ont Med 10:22-‐23, 1991
6. Remington G. New drugs in the treatment of schizophrenia. Contemp Psychiatry 1(suppl):3-‐6, 1992
7. Remington G, Bezchlibnyk-‐Butler K. Treatment of neuroleptic-‐induced extrapyramidal symptoms with antiparkinsonian drugs. Markham: Knoll Inc, 1993
8. Remington G. Extrapyramidal movement disorders: a video program. STA Communications, 1994
9. Remington G, Seeman MV, Wasylenki D. Schizophrenia management simplified. Patient Care 5:17-‐29, 1994
10. Annable L, Jones B, Nair V, Remington G, Williams R. Psychopharmacology. J Psychiatr Neurosci, 19(suppl 1):29-‐33, 1994
11. Remington G. Treatment options in refractory schizophrenia. Curr App Psych 2:1-‐3, 1995
12. Remington G. Selecting a neuroleptic and side effects. Child & Adolescent Psychopharmacology News, 2:1-‐5, 1997
13. Remington G. The development of novel neuroleptics and management of neuroleptic-‐induced extrapyramidal symptoms (EPS). Psych Med 1:2-‐7, 1996
14. Remington G. Safety of newer antipsychotic drugs. Curr App Psych 5:6-‐7, 1996
15. Remington G. Current issues in treatment-‐resistant schizophrenia. Can J Diag March (suppl):7-‐10, 1998
16. Remington G. Where do the “old” antipsychotics fit in today’s treatment? J Psychiatry Neurosci 24:192, 1999
17. Remington G. Novel antipsychotics: integrating PET data and clinical use. Can J Diag March (suppl):3-‐5, 1999
18. Faulkner G, Cohn T, Remington G. Interventions to reduce weight gain in schizophrenia. Schizophr Bull 33:654-‐656, 2007
45
Gary Remington
November 5, 2015